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Moringa leaves (ML), have been recognized for their protective effects against chronic disease.
To evaluate the protective effects of ML on hepatic steatosis and systemic inflammation, we
used the guinea pig model. Male Hartley guinea pigs were assigned (n=8/group) to consume
either a control diet (0 g Moringa), Low Moringa (LM) (10 %) or High Moringa (HM) (15%)
diets, which were supplemented with 0.25% dietary cholesterol to induce hepatic steatosis.
After 6 weeks, blood, liver, and adipose tissue were collected for determination of plasma lipids
and lipoproteins, tissue cholesterol concentrations, inflammatory cytokines and expression of
genes regulating hepatic cholesterol and triglyceride metabolism. There were no differences in
plasma total cholesterol, LDL, HDL, triglycerides, glucose or insulin among groups. However,
medium HDL concentrations as measured by nuclear magnetic resonance were higher and
plasma lecithin cholesterol acyl transferase activity was higher in both Moringa groups
compared to controls suggesting HDL metabolism was affected. Hepatic total cholesterol and
triglycerides exhibited a dose response effect with the lowest values observed in the HM group
(p < 0.01). The hepatic cytokines interleukin (IL)-1, 1L-10 and interferon γ were lowest in
the HM group, intermediate in the LM and highest in the control group (p<0.05). There was a
lower degree of steatosis and lipid accumulation in livers in the guinea pigs fed the HM
compared to the other groups in agreement with hepatic cholesterol and triglyceride
concentrations. Guinea pigs fed ML had lower gene expression of cluster of differentiation 68
and sterol regulatory element binding protein1c compared to controls (p<0.05).

Manal Almatrafi, PhD- University of Connecticut, 2017
Expressions of diglyceride acyl transferase and peroxisome proliferator-activated receptor
γwere lowest in the HM, intermediate in LM and highest in the control group (p< 0.01). The
high cholesterol diet resulted in accumulation of cholesterol and inflammation in the adipose
tissue, which was not prevented by Moringa treatment. We conclude that ML protect against
hepatic steatosis by affecting genes involved in synthesis and uptake of hepatic lipids resulting
in lower concentrations of cholesterol and triglycerides and reduced inflammation, however,
plasma lipids and adipose tissue cholesterol and inflammation were not affected significantly
by ML consumption.
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Chapter 1
Introduction

1

Hypercholesterolemia is defined as a lipoprotein metabolic disorder characterized by high total
and LDL cholesterol, which are considered the most important risk factors in the development
and

progression

of

atherosclerosis

and

cardiovascular

disease

(CVD)

(1).

Hypercholesterolemia causes major problems to society because of the close correlation
between CVD and lipid abnormalities (2).

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
and is considered a hepatic manifestation of metabolic syndrome (3, 4). NAFLD is
characterized by the accumulation of fat in the liver without a history of alcohol abuse (5). The
spectrum of NAFLD includes simple fatty liver, and non-alcoholic steatohepatitis (NASH),
which shows steatosis and inflammation and may progress to liver cirrhosis, hepatocellular
carcinoma, and advanced liver disease (6). In the liver, mitochondrial dysfunction, oxidative
stress, and hepatocyte apoptosis lead to hepatocellular injury. In addition, lipotoxic mediators
and intracellular signals activate Kupffer cells, which initiate the inflammatory response and
development of fibrosis (7).

Natural compounds from plant sources have been used effectively in the treatment of
dyslipidemias and NAFLD. The World Health Organization (WHO) reported that 80% of the
populations from Africa and Asia use traditional medicine for primary health care (8, 9). For
example, diets which are high in antioxidants including polyphenols (10), carotenoids and
minerals have been useful in reducing inflammation and oxidative stress (11). Moringa oleifera
(MO) is a plant that belongs to the monogeneric family Moringaceae. Most recent studies have
been concentrated on the medicinal uses of MO in addition to the important phytochemical and
pharmacological properties of different parts of the plant. Studies have reported the beneficial
effects of MO on chronic disease (12, 13, 14). Nearly every part of MO, including the roots,
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leaves, fruit (pods), seed, and seed oil have been used for various biological activities, including
anti-diabetic agents (15), hypotensive agents (16) cardiovascular action, regulation of thyroid
hormone status (17), antitumor agent and protection against oxidative stress (18) and treatment
of inflammation (19). However, there are still some gaps in the literature related to the effects
of Moringa leaves on hepatic steatosis.

Guinea pigs are similar to humans in the different responses to dietary cholesterol as hyper- or
hypo-responders (19). Accumulation of hepatic cholesterol is associated with increased plasma
cholesterol concentrations when dietary cholesterol is increased. The guinea pigs handle the
increased hepatic cholesterol by suppressing Hydroxyl methylglutaryl-CoA (HMG-CoA)
reductase activity and decreasing the LDL receptor in hepatic membranes (20, 21). In addition,
guinea pigs have been shown to respond to phytochemicals similarly to humans (22, 23, 24).

Therefore, the main objective of this study was to evaluate the protective effects of MO on
hepatic steatosis in an appropriate animal model, the cholesterol-fed guinea pig (25).

We hypothesized that MO leaves would prevent hepatic steatosis in the cholesterol fed guinea
pig by altering gene expression of key regulators of cholesterol and triglyceride metabolism.

There were three main objectives to this project, which were to evaluate:
Objective 1: Effects of Moringa leaves on plasma lipids, lipoprotein subfraction and size and
on lipoprotein metabolism.
Hypothesis 1: Moringa leaves reduce plasma lipids, atherogenic lipoproteins and modify HDL
metabolism.
Objective 2: Effects of Moringa leaves on hepatic steatosis
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Hypothesis 2: Moringa leaves prevent hepatic steatosis by altering expression of genes
involved in lipid accumulation and uptake.
Objective 3: Effects of Moringa leaves on adipose tissue.
Hypothesis 3: Moringa leaves decrease inflammation in adipose tissue

4

References
1. Rerkasem K, Gallagher PJ, Grimble RF, Calder PC and Shearman CP. Managing
hypercholesterolemia and its correlation with carotid plaque morphology in patients
undergoing carotid endoterectomy (A Review). Vascular Health Risk Manage.2008;
4(6):1259-1264.
2. Matos SL, Paula H, Pedrosa ML, Santos RC, Oliveira EL, Chianca Jr DA and Silva ME.
Dietary models for inducing hypercholesterolemia in rats. Brazilian Archives Biol.
Technol.2005;48(2): 203-209.
3. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the
multiple parallel hits hypothesis. HEPATOLOGY. 2010;52:1836-1846.
4. Takahashi Y, Inui A, Fujisawa T, Takikawa H, and Fukusato T. Histopathological
characteristics of non-alcoholic fatty liver disease in children: comparison with adult cases.
Hepatol Res. 2011; 41:1066-74.
5. Finelli C and Tarantino G. Is there any consensus as to what diet or lifestyle approach is the
right one for NAFLD patients? J Gastrointestinal Liver Dis. 2012; 21:293-302.
6. Ibrahim MA, Kelleni M and Geddawy A. Nonalcoholic fatty liver disease: current and potential
therapies. Life Sciences. 2013; 92:114-8.
7. Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, et al. Nonalcoholic fatty liver
disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007;18(3):184-95.
8. Nadkarni, KM. ‘The Indian MateriaMedica;” vol. 1, Third Ed. Popular Book Depot, Bombay,
1982; 811-816.
9. Murray DR and Freeman GL. Proinflammatory cytokines. Predictors of a falling health?
Circulation. 2003; 107:1460-1462.
10. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type- 2
diabetes. Diabetes Care. 2004; 27:813-823.
11. Serafini M, Bellocco R, Wolk A and Ekstrom AM. Total antioxidant potential of fruit and
vegetables and risk of gastric cancer. Gastroenterology 2002;123:985–91.
12 Di Matteo V and Esposito E. Biochemical and therapeutic effects of antioxidants in the
treatment of Alzheimer’s disease, Parkinson's disease, and amyotrophic lateral sclerosis. Curr
Drug Target CNS Neurol Disorders 2003; 2:95–107.
13. Kumaran A and Karunakaran RJ. Antioxidant and free radical scavenging activity of an
aqueous extract of Coleus aromaticus. Food Chem 2006; 97:109–14.
14. Makonnen, EA, Hunde S andDamecha G. Hypoglycemic effect of Moringa stenopetala
aqueous extracting rabbits. Phytotherapy Research 1997; 11:147-148.
15. Faizi, S., Siddiqui B, Saleem R, Aftab K, Shaheen F and Gilani A. Hypotensive constituents
from thepods of Moringa oleifera. Planta Med. 1998;64: 225–228.
16. Tahiliani P and Kar A. Role of Moringa oleifera leaf extract in the regulation of thyroid
hormone status in adult male and female rats. Pharmacol. Res. 2000; 41:319-323.
17. Anwar F, Latif S, Ashraf M and Gilani A. Moringa oleifera: A food plant with multiple
medicinal uses. Phytother Res.2007, 21, 17–25.
18. Mahajan S, Banerjee A, Chauhan B, Padh H, Nivsarkar M and Mehta A. Inhibitory effect of
n-butanol fraction of Moringa oleifera Lam. Seeds on ovalbumin-induced airway inflammation
in a guineapig model of asthma. Int. J. Toxicol 2009; 28:519- 527.
19. Fernandez ML, Lin ECK, Trejo A and McNamara DJ. Prickly pear (Opuntia sp) reverses low
density lipoprotein (LDL) receptor suppression induced by a hypercholesterolemic diet in
guinea pigs. J Nutr. 1992; 122:2330-2340.
20. Fernandez ML. Dietary cholesterol provided by eggs and plasma lipoproteins in healthy
populations. Curr Op Med Nutr Met Care. 2005; 9:8-12.

5

21. Murillo AG, Aguilar D, Norris GH, DiMarco DM, Missimer A, Hu S, Smyth JA, Gannon S,
Blesso CN, Luo Y, and Fernandez ML. compared with powdered lutein, a lutein nanoemulsion
increase plasma and liver lutein protect against hepatic steatosis and affect lipoprotein
metabolism in guinea pigs. J Nutr. 2016; 146:1961-1969.
22. Zern TL, West KL and Fernandez ML. Grape polyphenols decrease plasma triglycerides and
cholesterol accumulation in the aorta of ovariectomized guinea pigs.J. Nutr.2003;133: 2268–
2272.
23. Kim JE, Clark RM, Park Y, Lee J and Fernandez ML. Lutein decreases oxidative stress and
inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr ResPrac
2012; 6:113-119.
24. deOgburn R, Aguilar D, Volek J, Smyth JAand Fernandez ML. “Guinea Pigs Present
Hypercholesterolemia, Hepatic Steatosis and Liver Injury Congruent with Cholesterol-Induced
Non-Alcoholic Fatty Liver Disease Following a Dietary Cholesterol Challenge”. EC Nutrition
2015;1.1:29-40.

6

Chapter 2
Literature Review

7

Cholesterol definition
The cholesterol molecule has a steroid structure and hydrocarbon side chain. Cholesterol has
numerous functions in the human body. It is a precursor for steroid hormones, vitamin D and
bile acids, and a structural component of cell membranes and lipoprotein particles. The
substrate for cholesterol synthesis is acetyl CoA, an intermediate of fat, carbohydrate and
protein metabolism (1). Practically, all cells have the ability to synthesize their cholesterol,
despite the capacity of the gastrointestinal tract to absorb large quantities. However, only
hepatocytes have the ability for degrading cholesterol and eliminating it from the body (2).

Exogenous and endogenous cholesterol
In the body, cholesterol includes both dietary sources absorbed from the intestine and
endogenous sources (produced in the liver and peripheral tissues) (3). The human diet
supplies∼400 mg of cholesterol daily and the liver secretes ∼1 g daily (4). About 50% of the
cholesterol is absorbed in the intestine; the remainder is excreted in feces (5).

Exogenous cholesterol is absorbed by enterocytes which also contain cholesterol from
endogenous sources. Endogenous cholesterol is obtained from three sources; non-dietary
cholesterol absorbed from the lumen, cholesterol derived from plasma lipoproteins and
cholesterol synthesized de novo (6, 7). Cholesterol is transported mainly as esterified
cholesterol by the lymphatic system. The HDL protein particle accumulates cholesteryl esters
by the esterification of cholesterol by Lecithin-cholesterol acyltransferase (LCAT). Two
enzymes which are involved in the esterification of cholesterol are cholesterol esterase (8) and
acyl-CoA cholesterol acyltransferase (ACAT) (9).
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The major precursor of cholesterol synthesis is acetyl- CoA which is converted to hydroxyl
methylglutaryl-CoA (HMG-CoA) and then gives rise to mevalonic acid (MVA) by HMGCoA
reductase (16). The daily fecal loss of cholesterol from bile and desquamated cells is 550 mg,
while 250 mg comes from unabsorbed bile salts. A total of about 900 mg must therefore be
derived from the diet or synthesized each day (10).

Cholesterol absorption
In Western populations, cholesterol intake is around 200–600 mg/day, from which 40-80% is
absorbed (11, 12). Approximately, 10–15% of dietary cholesterol is esterified, and before
absorption is cleaved by a pancreatic enzyme, carboxyl ester lipase, so, most of the dietary
cholesterol does not require pancreatic hydrolysis (13).

The intestine has important functions in regulating cholesterol absorption in the body. Intestinal
cholesterol is derived from sloughed cells of the intestinal lining, dietary sources and direct
secretion via bile. The absorption of cholesterol is complex, involving a balance between
transport into the enterocytes [by the Niemann-Pick C1 -like 1 (NPC1L1) protein], and
transport out of the enterocytes by ATP-binding cassette (ABC) G5/8 and possibly by
transintestinal cholesterol efflux (14).

Cholesterol absorption is dependent on the velocity of intestinal transit, as it increases with a
slow transit time and decreases with rapid transit under physiological conditions or after
pharmacological stimulation of intestinal movement (15). In addition, detergent capacity of the
bile acid species prevailing in the enterohepatic circulation defines the cholesterol-solubilizing
capacity of bile acid micelles in both bile and intestinal contents (16).
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A diet-related factor which influences cholesterol absorption is dietary fiber due to physical
interactions within the intestinal lumen. Viscous or gel-forming soluble fiber binds bile acids
in the intestine, promoting their fecal elimination and thereby stimulating the hepatic
catabolism of cholesterol to bile acids (17). Also, soluble fiber could inhibit cholesterol
absorption through its effect of increasing the thickness of the unstirred water layer overlaying
the intestinal mucosa (18).

Plant sterols inhibit cholesterol absorption by competition with cholesterol due to their
hydrophobicity and poor absorbability, which remain in intestinal micelles and interfere with
the micellar solubility of cholesterol (19).

Lipoproteins
The majority of lipids (cholesterol, phospholipids and triglyceride) are carried in plasma by
large complex particles called lipoproteins. The densities of these lipoproteins are related to
the relative amounts of lipids to proteins in the complex. The higher the protein content, the
higher the density of the lipoprotein. According to their density, lipoproteins are classified into;
chylomicrons (lowest density lipoproteins) followed by chylomicron remnants, very lowdensity lipoproteins (VLDLs), intermediate density lipoproteins (IDLs), low density
lipoproteins (LDLs), and high-density lipoproteins (HDLs).

Chylomicrons
Dietary cholesterol is transported from the intestine to inside the body by chylomicrons (CM),
a triglyceride rich lipoprotein characterized by the presence of ApoB-48 (20). CM passes
through the lymphatic system and reaches the bloodstream (21). In the lymph and blood, CM
acquires other apolipoproteins such as apoCI, apoCII, apoCIII and apoE. ApoCII activates the
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endothelial cell-associated lipoprotein lipase (LPL), which hydrolyzes the triglycerides from
the core of CM and the resulting free fatty acids (FFA) are transported to the extra hepatic
tissues for energetic needs or storage. CM remnants are taken up by the liver via the hepatic
LDL receptor (LDL-R) and LDLR-related protein-1 (LRP1) through the interaction with
ApoE.

Very low density lipoprotein (VLDL)
Very low-density lipoprotein (VLDL) another class of triglyceride-rich lipoprotein is
synthesized and secreted by liver and contains ApoB100, apoE, apoCII and apoCIII and is also
packed up with endogenous cholesterol, lipid soluble vitamins and carotenoids (22). In
addition, VLDL triglyceride content is hydrolyzed resulting in cholesterol-rich remnant
particle and ultimately LDL (23).

Production of VLDL by the liver has been demonstrated in different studies utilizing the rat
(24, 25, 26) and monkey (27) liver and hepatocytes grown in short-term culture (28). In
addition, studies of subcellular fractionation of the liver (29) reported that precursors of plasma
VLDL (300-1000 A°, diameter particles) are present in the Golgi region of the hepatocyte.
Although the majority of plasma VLDL is synthesized in and secreted from the liver, the
intestine also produces lipoproteins similar in size and lipid composition to plasma VLDL
which contain a low molecular weight form of apolipoprotein B (30)

LDL is composed of a hydrophilic surface layer of phospholipids (PL), free cholesterol and
hepatically-derived apo B100. The core of the particle contains esterified cholesterol and
triglyceride together with the fatty acid tails of the PL (31). LDL is sub-divided according to
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size into a pattern A and a pattern B. Pattern B, termed small dense LDL has been associated
with an increased risk for atherosclerosis (32).

LDL is the best-known lipoprotein not only due to the receptor for LDL which was discovered
by Goldstein and Brown (33) and the importance of the receptor in maintaining cholesterol
homeostasis but also because statins, which inhibit HMG-CoA reductase, were found to up
regulates the LDL receptor, lower cholesterol in the blood stream and reduced CVD (34). Also,
LDL was reported to supply cholesterol all over the body to maintain cell viability and to
provide cholesterol for the synthesis of the steroid hormones (35).

The correlation between high LDL cholesterol (LDL-C) and increased risk for CHD has been
well documented (36). A predominance of small, dense LDL particles, which are considered
to be more atherogenic than the larger more buoyant cholesteryl ester (CE) enriched fraction
(Pattern A subclass), would be representative of the Pattern B subclass (37). Small LDL
subclass was showing to be associated with a 3-fold increase in CHD risk due to the easy
entrance of the smaller particles into the arterial wall and binding to the proteoglycans and their
increased susceptibility to oxidation (38, 39, 40). This enhanced susceptibility may be due to
lowered tocopherol content or increased polyunsaturated fat concentration in the denser LDL
subclass (41, 42).

High density lipoprotein (HDL)
HDL is the smallest and densest plasma lipoproteins. They comprise a heterogeneous mixture
of sub-populations containing particles of differing size (43). They contain a number of
apolipoproteins, with apoA-I accounting for about 70%, apoA-II about 20%, with smaller
amounts of several others, including apoA-IV, apoE, the Capoli- poproteins, apoD, apoL, and
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apoM. HDL subclasses can be grouped as large HDL (8.8–13 nm), medium HDL (8.2–8.8 nm),
and small HDL particles (7.3–8.2 nm) according to the nuclear magnetic resonance (NMR)
spectroscopy method. Large HDL has been negatively associated with CVD (44, 45) while,
low concentrations of large HDL have been associated positively with coronary artery disease
in patients with Type 1 diabetes (46). HDL possesses several functions to protect against CVD
including promotion of cholesterol efflux from cells, antioxidant properties, inhibition of
vascular inflammation, anti-thrombotic properties, an ability to improve endothelial function
as well as promotion of endothelial repair, promotion of angiogenesis,

stimulation of

pancreatic β cells to synthesize and secrete insulin, enhancement of insulin sensitivity and
improvement in diabetic control and may also be involved in the innate immune system (47).

The antiatherogenic function of HDL is its ability to boost the efflux of cholesterol from cells.
Also, HDL has antioxidant, anti-inﬂammatory, and antithrombotic properties The antiinﬂammatory functions of HDL include limiting lipid peroxidation, inﬂuencing expression of
cytokines, modulating recruitment/adhesion of monocytes, and altering other aspects of
endothelial function (48). Among other functions, HDL reverses endothelial cell dysfunction,
stimulates prostacyclin production (which is both vasodilatory and antithrombotic), inhibits
endothelial cell apoptosis, decreases platelet aggregability, and inhibits LDL oxidation (48).
The major function of HDL may be reverse cholesterol transport (RCT); however, an important
function relates to its ability to protect LDL from oxidation. Thus, HDL can reduce the
atherogenicity of LDL (49).

In addition to the role of favoring RCT, HDL serves several antiatherogenic functions, such as
limitation of the oxidation of PL within LDL (50). By limiting LDL oxidation, HDL plays a
key anti-inﬂammatory role in slowing atherogenesis. HDL inhibits the oxidation of LDL via
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antioxidant enzymes and apo- lipoprotein (apo) A-I (51). Also, HDL normally attenuates
cytokine-induced adhesion molecule expression on endothelial cells and promotes efflux of
cholesterol out of vascular macrophages and the arterial wall itself, limiting the formation of
inﬂammatory foam cells (52).

HDL appears to have evolved as part of the innate immune system, which in part uses an
enhanced oxidative state as a non-specific means of protecting against many pathogens. In the
absence of acute or chronic inflammation, HDL is anti-inflammatory in mice, rabbits, and
humans (53). The major apolipoprotein of HDL is apoA-I, which may be altered by oxidative
processes in patients with atherosclerosis. The ability of HDL to inhibit the inflammatory
properties of oxidized PL and LDL also had been reported (53).

Dietary cholesterol
Several studies reported that there is an individual variation in regard to responses to dietary
cholesterol (54). Elevated plasma cholesterol is considered a risk factor for heart disease (55).
Cholesterol challenges above the usual intake; disturb cholesterol homeostasis resulting in
metabolic disorders such as dyslipidemia, endothelial dysfunction, hepatic steatosis, CVD and
systemic inflammation (56). One study in humans reported that, dietary cholesterol increased
plasma TC and LDL-C without a consequent increase in HDL-C which is a major risk factor
for atherosclerosis and CVD (57). However clinical studies from our laboratory have shown
that, dietary cholesterol increased both LDL and HDL (58, 59) or on some occasions only
increased HDL (60).

Eggs are the richest sources of cholesterol in the diet. Numerous studies failed to find any
correlation between the intake of eggs and CVD risk (61). This lack of correlation might be
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due to the other factors found in eggs that may influence CVD risk, such as antioxidant
carotenoids (lutein and zeaxanthin) (62). Also, eggs are a rich source of PL, which area
potential source of bioactive lipids and affect inflammation, cholesterol metabolism, and HDL
function (63). Egg PL, such as phosphatidylcholine (PC) and sphingomyelin (SM) are reported
to reduce cholesterol and fatty acids (FA) absorption by possibly interfering with lipid
mobilization from mixed micelles (64).

Egg PL appears to influence hepatic lipid metabolism through effects on cholesterol and bile
acid synthesis, fatty acid (FA) oxidation, and lipoprotein secretion (64). Hepatic lipid levels
showed to be decreased by dietary PL in animals by inhibiting intestinal lipid absorption and
affecting hepatic nuclear receptors that regulate lipid metabolism (65). SM and PC are reported
to regulate cholesterol absorption and inflammation and the incorporation of egg PL into HDL
appears to be a major factor in the cholesterol-accepting capacity of this lipoprotein (66).
Ovotransferrin, a protein present in egg, has antibacterial properties, antiviral activity, as well
as antioxidant and anti-inflammatory properties (67). Also, egg yolk proteins including
vitellogenin, lipovitellin and phosvitin have been shown to participate in the immune defense
system, capable of killing bacteria and viruses as well as promoting phagocytosis activity (68).

Several experimental studies confirmed that atherosclerosis was directly alleviated by HDL
(69) and improved CVD outcomes by its ability to remove cholesterol from the arteries via
RCT. Regular consumption of egg yolk has been shown to increase plasma HDL-C and
increase mean size of HDL particles in healthy (70), overweight (71), and metabolic syndrome
(MetS) individuals which may be due to the high intake of egg PL (72). Also, in addition to
increasing HDL cholesterol, egg yolks also increase plasma lecithin-cholesterol acyltransferase
(LCAT) activity and serum cholesterol efflux capacity (73, 74).
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Dietary intake of egg may also reduce inflammation. Consumption of eggs resulted in a
reduction in plasma C-reactive protein (CRP) and an increase in adiponectin in overweight men
(75). Also, egg consumption improved plasma inflammatory markers in adults with MetS. In
combination with carbohydrate restriction, egg intake led to decreases in plasma tumor necrosis
factor (TNFα) and serum amyloid A in men and women with MetS (76). Egg yolk contains a
good amount of choline as PC which has been shown to be inversely correlated with serum
inflammation markers in healthy adults (77).

Because Increased LDL-C has been suggested as a major risk factor for CVD, dietary
guidelines to prevent CVD were established as 300 mg/d (78). Egg is a major source of dietary
cholesterol (200 mg cholesterol). On the other hand, eggs contain other compounds such as
minerals, folate, vitamins B, proteins, and mono-unsaturated fatty acids which reduce the risk
of CVD (79). However, the new dietary guidelines (80) have removed the upper limits for
dietary cholesterol (81) confirming that eggs do not increase the risk for heart disease.

Dietary cholesterol has been shown to increase the formation of larger LDL (82) and HDL
(83), increase LCAT (84) and CETP (85) activities, and boost cholesterol efflux from
macrophages (86) indicating an enhancement of RCT. This information confirms the lack of
correlation between dietary cholesterol and CVD as indicated in multiple epidemiological
studies (87).

In individuals classified with MetS, cholesterol intake has not shown any detrimental effect on
lipoprotein profiles, contrary to the belief that eggs and dietary cholesterol should not be
provided to patients at risk for CVD (88). In addition, studies conducted in individuals with

16

MetS have reported that consuming an additional 550 mg of dietary cholesterol (via eggs) for
12 weeks resulted in a significant increase in HDL with no changes in LDL (83).

Small LDL possess a number of features that make them more atherogenic, including their
ability to penetrate the arterial wall and become easily oxidized, making them a perfect target
for macrophages, which initiate the whole process of atherosclerosis (89). In the situation of a
low carbohydrate diet, a challenge of additional 640 mg of cholesterol per day resulted in higher
concentrations of the large LDL particle and reduced number of the small atherogenic LDL,
which is considered a less atherogenic lipoprotein profile (82).

However, in animal models, it is a different situation because they are fed with very high
amounts of dietary cholesterol in order to induce atherosclerosis, systemic inflammation or
liver injury. For example, in guinea pigs, it has been shown that a challenge of 0.25% of dietary
cholesterol (equivalent to 2500 mg/day in the human situation) for six weeks results in
hypercholesterolemia when compared to a control group, associated with high plasma activity
of liver enzymes, alanine amino transferase (ALT) and aspartate amino transferase (AST),
which are biochemical indicators of hepatic damage. In addition, high cholesterol feeding
resulted in increased hepatic accumulation of TG along with total, free, and esterified
cholesterol, resulting in modest hepatic steatosis. At the same time, high cholesterol was
capable of causing hepatic inflammation and injury in liver tissue as cell necrosis (90).

Cholesterol balance and homeostasis
Cholesterol balance involves consideration of both bile salts and cholesterol because bile salt
molecules are formed by enzymatic modification of cholesterol. Hepatocytes clear bile salts
from the portal blood and re-secrete them into bile. The conversion of cholesterol to bile acids
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occurs at a rate that exactly balances the loss into the feces. This is achieved through sensing
the concentrations of bile salts in both the liver and intestine by nuclear hormone receptor
(FXR). The net synthesis of daily cholesterol is equal to the amount of cholesterol lost in the
feces minus the dietary cholesterol (~ 1.2 g/day). This takes into consideration that the amount
of cholesterol absorbed was equal to the amount lost (91).

Cholesterol levels in the liver play an important role in the body since the liver is the organ
involved in the maintenance of whole body cholesterol homeostasis. When cholesterol enters
by LDL endocytosis to the liver, it becomes part of the free cholesterol pool which is
metabolically active and can be used as a substrate for different enzymes. The liver is important
for regulating cholesterol homeostasis in the body through several mechanisms (92). The most
important one is the regulation of HMG-CoA reductase, the rate-limiting enzyme in cholesterol
synthesis (93). HMG-CoA reductase is found in all tissues, but the highest level of this enzyme
and the feedback regulation by dietary cholesterol occurs in liver. Another enzyme used by the
liver is Acyl CoA cholesteryl acyltransferase (ACAT) and together with HMG-CoA reductase
it is involved in controlling the intracellular and extracellular levels of cholesterol (94). ACAT
esterifies free cholesterol with fatty acyl CoA, leading to the reduction of toxic effects of
excessive cholesterol in cell membranes. The liver also has the highest concentrations of the
LDL receptor (LDL-R), which is used to remove LDL cholesterol from circulation (8). In
addition, cholesterol 7α-hydroxylase (CYP7A1), the initial enzyme in bile acid biosynthesis
uses free cholesterol as a substrate for the synthesis of bile acids. Cholesterol homeostasis is
maintained when these enzymes respond to changes in the hepatic bile acid pool (95, 96).

Cholesterol in the liver is determined by a balance between LDL uptake from plasma and
intracellular de novo synthesis in addition to cholesterol secretion via VLDL and dietary
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cholesterol coming from the diet via chylomicron remnant. Liver cells have LDL receptors that
are responsible for feedback inhibition. The subsequent liberation of free cholesterol into the
cytosol has three main effects: (1) inhibition of HMG-CoA reductase activity thereby
decreasing the rate of de novo cholesterol synthesis; (2) increase of the activity of ACAT, the
enzyme that esterifies intracellular cholesterol, yielding a more non-polar molecule that
coalesces into intracellular lipid droplets; and (3) inhibition of LDL receptor synthesis,
resulting in a decreased uptake rate of LDL from plasma (97).

HMG-CoA Reductase
HMG-CoA reductase is the rate limiting and regulatory enzyme of the metabolic pathway of
cholesterol synthesis. It is a transmembrane protein, containing 8 domains, which are anchored
in the membrane of the endoplasmic reticulum. It is the major target of statins, cholesterol
lowering drugs, which are the best-selling pharmaceutical drugs in the world (98). HMG-CoA
reductase can be present in active and inactive forms. The inactive form of the enzyme appears
to be converted into the active one by dephosphorylation of the enzyme (99, 100).

Regulation of HMG-CoA reductase occurs by feedback at 4 different levels; 1) regulation of
transcription of the reductase gene when levels of cholesterol decrease; 2) translation of the
HMG-CoA reductase mRNA, which is inhibited by farnesylpyrophosphatase; 3) degradation
of intact reductase by endoplasmic reticulum (ER)-associated degradation when the level of
sterol increases. A final regulation is phosphorylation and inactivation by an AMP-activated
protein kinase (101, 102, 103).
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Acyl CoA-cholesterol acyltransferase (ACAT)
ACAT is a membrane-bound protein that utilizes long-chain fatty acyl-CoA and cholesterol as
substrates to form cholesteryl esters and plays an important role in cellular cholesterol
homeostasis in various tissues. ACAT is the enzyme primarily responsible for cholesterol
esterification in the liver and intestine. To maintain cholesterol balance, ACAT esterifies
excess free cholesterol into cholesteryl esters. The cholesteryl esters produced become part of
the components of apoB-containing lipoproteins synthesized in the liver. ApoB-containing
lipoproteins enriched in cholesteryl esters increases by increased activity of ACAT, which is
regulated by the amount of free cholesterol present in the cell, which usually is not enough to
saturate the enzyme. Another function of ACAT is its involvement in cholesterol absorption in
the intestines which can be packaged into chylomicrons (104).

The family of ACAT consists of ACAT1, ACAT2 and acyl-CoA: diacylglycerol
acyltransferase 1 (DGAT1) (105, 106, 107, 108). These enzymes are founding members of the
membrane-bound O-acyltransferase (MBOAT) enzyme family. MBOATs are multispan
membrane enzymes that utilize long-chain or medium-chain fatty acyl-CoA and a hydrophobic
substance as their substrates. ACAT1 is expressed in many different tissues and cell types,
including hepatocytes and Kupffer cells of the liver, adrenal glands, neurons, and macrophages
(109). Parini et al. (110) demonstrated the presence of both ACAT1 and ACAT2 in adult human
hepatocytes. In mice and in monkeys, the ACAT1/ACAT2 distribution in various tissues is
similar to that in humans except for at least one important difference, that ACAT2 is highly
expressed in the livers of mice and monkeys under normal conditions (111).

ACAT is regulated by different factors including; 1) dietary cholesterol which increases in the
enzyme activity in guinea pig, rats and rabbits (112, 113, 114); 2) by 25 hydroxycholesterol
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and mevalonate, both of which increase the activity (104); 3) by both LDL and free cholesterol
and reduced by a decrease in cholesterol availability (115).

The inhibition of this enzyme causes less cholesteryl ester formation leading to a decreased
secretion of VLDL. While less VLDL is being secreted from the liver, less VLDL is converted
to LDL resulting in decreases of LDL cholesterol in plasma (116). Also, ACAT inhibitors play
an important role as antiatherogenic compounds, decreasing cholesterol content of the arteries
and decreasing fatty streak formation (117).

Cholesterol 7α-hydroxylase (CYP7)
CYP7 is another important enzyme involved in the maintenance of cholesterol homeostasis in
the liver. Free cholesterol is used by CYP7 as a substrate for the synthesis of bile acids. It is a
protein localized in the membrane of the endoplasmic reticulum in hepatic parenchymal cells.
CYP7 is considered a rate limiting enzyme in bile acid synthesis (118). It catalyzes the
hydroxylation of cholesterol on carbon7. This enzyme is similar to HMG-CoA reductase,
which exhibits diurnal variation. It presents maximum activity at midnight and a minimum at
midday. This rhythm is present in rats and rabbits, where it is clearly determined by the levels
of mRNA (119).

CYP7 has negative feedback regulation by bile acids, which appears to be at the level of
transcription. In the liver, bile acids activate a nuclear receptor, farnesoid X receptor (FXR),
which induces an atypical nuclear receptor small heterodimer partner, resulted in inhibits
nuclear receptors, liver-related homolog-1, and hepatocyte nuclear factor 4α and results in the
inhibition of transcription of the critical regulatory gene in bile acid synthesis, cholesterol 7αhydroxylase (CYP7A1). The activity of CYP7 is increased by the lack of reabsorption of bile
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acids in the hamster (120). These results support the negative feedback regulation of bile acids.
Also, CYP7 activity and mRNA levels are decreased by hydrophobic bile acids, which do not
undergo rapid metabolism to more hydrophilic ones.

CYP7 activity is increased after

cholestyramine treatment due to the increased demand for bile acids, while diminished in a
state of vitamin C deficiency. Dietary cholesterol and thyroid hormone treatment cause an
increase in the activity of the enzyme, as well as increasing the level of mRNA (121).

LDL receptors
The LDL receptor (LDL-R) plays an important role in the lowering of plasma cholesterol. The
LDL-Ris up-regulated to maintain hepatic cholesterol homeostasis when there is an excess of
LDL cholesterol leading to the lowering of plasma LDL-C (122).The concentration of plasma
LDL-C is dependent on the number of hepatic LDL-R because increased numbers of LDL-R
lead to higher uptake of LDL particles and lower concentration of plasma LDL-C.

The liver compensates for increases in cholesterol intake by reducing the rate of de novo
cholesterol synthesis and in some cases, the rate of receptor- dependent LDL-C uptake. Since
the liver is the principal site of LDL catabolism, changes in hepatic LDL-R expression usually
result in reciprocal changes in plasma LDL concentrations (118). The two mechanisms most
commonly implicated in resistance to dietary cholesterol are 1) a diminished efficiency of
cholesterol absorption and 2) an enhanced capacity to convert cholesterol to bile acids. Both
mechanisms would reduce liver cholesterol and potentially lead to up-regulation of the LDLR pathway (123).
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Proprotein convertase subtilisin Kexin Type 9 (PCSK9)
PCSK9 is a key regulator in cholesterol metabolism, an enzyme encoded by the PCSK9 gene
in humans, which binds to the LDL-R thereby reducing the number of available hepatic LDLR leading to increased plasma levels of LDL-C. Treatment with estrogen, glucagon and a
cholesterol-enriched diet reduces PCSK9 expression, while it is increased by insulin. The
transcription factor SREBP-2 is partly involved in the hormonal and dietary regulation of
PCSK9 as induction of PCSK9. Circulating PCSK9 has a pronounced diurnal variation and is
strongly reduced during fasting in humans (124). These changes are presumably related to
oscillations in hepatic intracellular cholesterol levels mediated by SREBP-2. Growth hormone
treatment reduces circulating PCSK9 in men, whereas a ketogenic diet does not alter circulating
PCSK9 levels (124).

Guinea pigs as animal models for cholesterol metabolism
Guinea pigs have been demonstrated to be good models for cholesterol and lipoprotein
metabolism due to similarities to humans in the regulation of hepatic cholesterol homeostasis
and in the changes in lipoproteins induced by diet (125) or by drug treatment (126). The most
striking similarity between guinea pigs and humans is that the majority of circulating
cholesterol is transported in LDL (127). Similar to humans, guinea pigs experience different
responses to dietary cholesterol by which we could classify them as hyper- or hypo-responders
(127). Increasing dietary cholesterol results in accumulation of hepatic cholesterol and
increased plasma cholesterol concentrations (128). One of the first mechanisms by which
guinea pigs handle the excess of hepatic cholesterol is by suppressing HMG-CoA reductase
activity. Decreases in LDL receptor in hepatic membranes have also been observed (129).
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Another important feature in guinea pigs is that most of the cholesterol in liver is in the free
form similar to humans and increases proportionally with dietary cholesterol (130). Hepatic
CYP7 activity is not regulated by high cholesterol diets in guinea pigs. The inability of guinea
pigs to respond to high dietary cholesterol by increasing hepatic cholesterol catabolism may be
one of the reasons why this animal model is more responsive to dietary cholesterol. Thus guinea
pigs responses to dietary cholesterol are more consistent with human responses (131).

Guinea pigs have been found to have higher ACAT activity with higher levels of dietary
cholesterol by the increased substrate (free hepatic cholesterol) for this enzyme. Suppression
of hepatic apo B/E receptors in guinea pigs by high intake of dietary cholesterol leads to
increased hepatic cholesterol concentrations in addition to increased plasma LDL cholesterol
due to suppression of LDL receptors. Higher concentrations of cholesterol in the liver of guinea
pigs decrease HMG-CoA reductase activity and increase ACAT activity, because of increases
in substrate availability. The major mechanism responsible for the elevated plasma LDL
cholesterol concentrations is the suppression of LDL receptors by dietary cholesterol
(131,132).

Regulation of cholesterol homeostasis in liver varies between male and female guinea pigs
(133, 134, 135, 136). When male guinea pigs were fed high dietary cholesterol, the activities
of HMG-CoA reductase and CYP7 increased while ACAT activity decreased with dietary
soluble fiber (pectin, guar gum or psyllium) (133,134). Compared to female guinea pigs fed
high dietary cholesterol, soluble fiber only marginally increased activities of HMG-CoA
reductase and CYP7 and marginally decreased activity of ACAT (135).
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Oxidative stress
Any chemical species containing unpaired electrons produce highly reactive free radicals
(137). Free radicals are formed as by-products of cellular function such as oxidative
phosphorylation which occurs in the mitochondria (138). These by-products are generally
reactive oxygen species (ROS) as well as reactive nitrogen species (RNS) (139).

Numerous studies reported that free radicals damaged cellular proteins, membrane lipids and
nucleic acids, and finally caused cell death. In contrast, the human body counteracts this
damage by the use of antioxidants, which are either endogenous, or supplied through foods
and/or supplements (exogenous) (140). Antioxidants could be categorized as enzymatic when
they break down and remove free radicals through enzymatic reactions such as superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSHPx). Non-enzymatic
antioxidants worked by interrupting free radical chain reactions such as vitamin C, vitamin E,
plant polyphenols, carotenoids, and glutathione (141).

Oxidative stress has a major role in the development of chronic and degenerative diseases such
as cardiovascular, cancer, autoimmune disorders, cataract, and neuro-degenerative diseases
(139). When the organism's capacity could not counteract the production of pro oxidant free
radicals action by antioxidant systems, the organism is exposed to oxidative stress (142,143).

Chronic inflammation
In obesity, the adipose tissue is associated with many of the inflammatory responses. Adipose
tissue mass induces the secretion of a number of inflammatory mediators including tumor
necrosis factor (TNF-α), interleukin (IL)-1β, IL-6, monocyte chemoattractant protein 1 (MCP1). This production of inflammatory adipokines has been shown to be involved in the
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development of insulin resistance and MetS (144,145). Chronic inflammation is characterized
by the up-regulation of biomarkers such as leukocyte count, serum and plasma concentrations
of acute-phase proteins, pro-inflammatory cytokines, chemokines, soluble adhesion molecules
and prothrombotic mediators (146).

Cholesterol metabolism plays a role in inflammation. The interaction of LDL with
macrophages in atherosclerotic plaques leads to an increase in inflammatory gene expression
(147). Numerous studies on animals showed that high dietary cholesterol led to an increase in
macrophage accumulation in the adipose tissue, increasing insulin resistance and chronic
systemic inflammation (9). Accumulation of cholesterol in the adipocytes has been shown to
be cytotoxic and is associated with recruitment of pro-inflammatory cells, and aggravated
systemic inflammation (148, 149).

Relation between oxidative stress and inflammation
Oxidative stress and inflammation are both linked to many chronic diseases, and induced by
each other (150). Reactive oxygen species (ROS) could stimulate production of oxidized LDL
(Ox LDL), which induced the activation of Peroxisome proliferator activated receptor γ
(PPARγ), and influenced the expression of downstream genes leading to foam cell formation,
inflammation and atherosclerosis. The induced macrophages secrete interleukin-1 beta (IL1b),
which may stimulate the smooth muscle cells (SMCs) to over-express platelet-derived growth
factor (PDGF), which may cause migration and proliferation of the SMCs. Also, Ox-LDL is
toxic to macrophages, which causes the apoptosis and necrosis of foam cells and the subsequent
release of their cellular contents, resulted in compose the necrotic core found in advanced
lesions (151). Some radicals also stimulate nuclear factor kappa (NF-κB) and P38 Mitogen
Activated Protein Kinase (p38-MAPK) leading to inflammatory responses (141). Also, cells of
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the immune system such as macrophages and leucocytes are recruited to the site of damage
during inflammation resulting in an over production of ROS, and consequently oxidative stress
(152). Natural antioxidants are important as therapeutic agents against oxidative stress and
inflammation-related diseases (143, 153). Bioactive components of antioxidant had the ability
to scavenge ROS, have an indirect impact on inflammation, and are also capable of interacting
directly with inflammatory pathways (152, 154).

Cytokines, proinflammatory markers and gene expression
The essential component of the immune response to pathogens and damaged cells is the
production of inflammatory markers. Cytokines are secreted by endothelial cells, T
lymphocytes, macrophages, monocytes, and platelets, Cytokines include: tumor growth factors
(TGFs), TNF- α, interleukins, interferons (IFNs), chemokines and colony stimulating factors
(CSFs); which participate in the control of the immune response. IL-4, secreted by T
lymphocytes, increased the activity of macrophage 12/15-lipoxygenase, which synthesizes 13hydroxyoctadecadienoic acid (13-HODE) and 15-hydroxyeicosatetraenoic acid (15-HETE)
from linoleic and arachidonic acids, respectively (155). Thus, this activation via IL-4 has been
shown to provide linkage for PPARγ and induce expression of CD36 in a PKC-dependent
manner (156). Also, other cytokines such as TGF-β, IFN-γ and IL-10 have an effect on CD36
expression. In monocytes, IFN-γ and TGF-β decreased the expression of CD36, while IL-10
increased both the expression of CD36 and ABCA1, favoring the uptake and clearance of
cholesterol by macrophages (157,158).

Adiponectin stimulates the secretion of anti-inflammatory cytokines blocking NF-kB which
inhibiting the release of TNF-α, IL-6, and chemokines and reducing inflammation (159).
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Adiponectin protects against FAs-mediated hepatocyte death and reduces fibrogenesis of
hepatic cells (160).

High doses of dietary cholesterol cause inflammation of adipose tissue resulted in reductions
in the levels of plasma high moeluclar weight adiponectin. Reduced adiponectin production
and signaling have been implicated in the development of NAFLD/NASH in mice and humans
(161). Since the liver is a major organ involved in cholesterol metabolism, high cholesterol
provided in pharmacological doses could cause hepatocyte dysfunction, fibrosis, and induction
of the development of early stages of nonalcoholic steatohepatitis (162).

Cholesterol challenge diets have shown to increase levels of circulating oxidized LDL (OxLDL) (163). This pro-atherogenic lipoprotein is internalized by scavenger receptor B1 (SRB1) and LDL related protein 1 (LRP-1) in macrophages leading to cell dysfunction and
production of pro-inflammatory cytokines and chemo-attractants and finally the formation of
foam cells, the official mark of atherosclerosis (164).

Cholesterol accumulation in adipose tissue increases macrophage infiltration which is
accompanied by increased levels of inflammatory cytokines TNF-α, MCP-1, and GMF-CSF.
Also, there is a reduction in the anti-inflammatory cytokine IL-10, decreased gene and protein
expression of sterol regulatory binding-element protein 1 (SREBP-1) and PPAR-γ2, resulting
in adipocyte dysfunction in adipose tissue from guinea pigs fed with high cholesterol (165).

Dietary cholesterol challenge, associated with a diabetogenic diet induced increased
macrophage infiltration in adipose and aortic tissue leading to progress of atherosclerosis and
accompanied with increased levels of systemic inflammation markers serum amyloid A and C-
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reactive protein (166). A dietary cholesterol challenge also leads to arrest of adipocyte
development and induces macrophage infiltration and inflammation in adipose tissue in guinea
pigs (167). Cholesterol efflux from cells is the cause for a decrease in cholesterol content.
LXRα and LXRβ control the expression of genes implicated in cholesterol efflux and involved
in cholesterol storage, catabolism and excretion (168). In addition to ABCA1, the hepatic
expression of ABCG5 and ABCG8 were increased during a high cholesterol diet by LXRα and
LXRβ and were involved in the cholesterol catabolism into bile acids (169).

Activation of nuclear receptors; PPARγ, LXRα, LXRβ and pregnane X receptor (PXR) are
accompanied by the accumulation of hepatic TG and response elements for these receptors are
found in the promoter regions of CD36, which established this gene as a common target in the
promotion of liver steatosis (170, 171, 172, 173). PPARγ coactivator-1-beta (PGC-1β) coactivates SREBPs and stimulates lipogenic gene expression contributing to hepatic lipid
synthesis. However, a high fat diet increased expression of PGC-1β resulting in reduction of
hepatic fat accumulation (174). This is described by an increase in circulating TG and
cholesterol (VLDL) influenced by PGC-1β co-activation of LXRα and stimulation of
lipoprotein transport. Its overall action leads to hyperlipidemia and atherosclerosis. Hepatic
overexpression of PGC- 1β with decreasing the expression and activity of PPARα and
increasing the expression of CD36 was sufficient to induce hyperlipidemia (175).

SREBP-1 has been shown to modulate the expression of the PPARγ gene at the transcription
level (176). PPARγ is involved in the transcription of several lipogenic genes that are critical
in adipocyte development (177). Inflammatory changes in adipocytes were shown to be more
receptive to TNF-α signaling and subsequent apoptosis, which might lead to macrophage
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infiltration and secretion of inflammatory cytokines, which could then result in a proinflammatory feedback loop (166).

Although increased CD36 expression is considered proatherogenic. CD36 is an 88 kDa
glycoprotein expressed on platelets, monocyte-macrophages, microvascular endothelial cells,
adipose tissue, skeletal muscles and heart.

CD36 deficiency is accompanied by; (1)

hyperlipidemia and increased remnant lipoproteins; (2) impaired glucose metabolism based
upon insulin resistance, and (3) mild hypertension, and comprises one of the genetic
backgrounds of the metabolic syndrome, leading to the development of CHD (178, 179, 180).

In fatty liver and in patients that develop hepatic steatosis or hepatocyte apoptosis, the
expression of CD36 is elevated compared to normal liver (181, 182). In NAFLD patients, CD36
is mainly found on the plasma membrane of hepatocytes and its elevated expression was
associated with insulin resistance (183).

Non-Alcoholic Fatty Liver Disease
Definition
NAFLD is the disease affecting liver which progresses from non-alcoholic fatty liver to
nonalcoholic steatohepatitis (NASH) to fibrosis and cirrhosis. It can be defined as the presence
of hepatic steatosis without ballooning degeneration and inflammation in the hepatocytes with
absence of significant alcohol consumption. Liver steatosis might be due to abnormal
triglyceride deposition in hepatocytes resulting from imbalance between the uptake of fat and
its oxidation and/or export. NASH is defined as the presence of fatty infiltration in the liver
resulting in ballooning and inflammation of the hepatocytes with or without fibrosis (184,185).

30

Epidemiology
Obesity, diabetes mellitus, and hyperlipidemia are main disease-related factors of NAFLD
(186). In the present time, NAFLD is one of the most common chronic and progressive liver
diseases in developed countries, with the number of people affected increasing rapidly (187).
NAFLD covers a wide spectrum, ranging from simple fat deposition changes to severe
steatohepatitis with fibrosis (188).

NAFLD is the most- widespread liver disease in the United States, affecting 15%-46% of adults
(200, 201). Obesity is the most important risk factor for NAFLD; the prevalence of NAFLD is
4.6 times greater in the obese population, and up to 74% of obese individuals have fatty livers.
The majority of patients with NAFLD have ‘‘simple steatosis’’ defined by excessive fat
deposition within hepatocytes in the absence of substantial inflammation or fibrosis. However,
around 10%-30% of patients with NAFLD develop nonalcoholic steatohepatitis (NASH),
characterized by varying degrees of inflammation and fibrosis, in addition to hepatic steatosis
which can progress to cirrhosis, liver failure, and hepatocellular carcinoma at different stages
in patients (186, 189).

Pathogenesis
The pathogenesis of NAFLD/NASH has not been fully elucidated, but the theory of how it is
formed has been recently accepted. First, excess fat accumulation occurs in hepatocytes, and
then secondary activity such as oxidative stress may cause NAFLD (192). It has been suggested
that lipid peroxidation is an important factor in the progression of NASH in rodent models
(193).
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Insulin resistance, characterized by increased hormone-sensitive lipase activity and increased
lipolysis of peripheral fat, is the most consistent pathogenic factor for hepatic steatosis (194).
Excess of dietary cholesterol intake (pharmacological doses) in animal models has been
reported to be an important risk factor for hepatic steatosis and progression to steatohepatitis
(195, 196).

Dietary interventions
Dietary interventions have a major role in treating obesity, insulin resistance, and NAFLD.
Monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) were reported
to have a protective role in the progression of NAFLD (197,198).

Dietary interventions for NAFLD include modifications of nutrients intake such as
carbohydrate and fat restriction; in addition, to use of antioxidants such as vitamins C, E and
polyphenols, betaine, anthocyanins and curcumin (199). A carbohydrate- restricted diet was
found to attenuate hepatic cholesterol accumulation induced by a cholesterol challenge in
guinea pigs (188). In addition, low-carbohydrate diets showed decreased serum ALT and
hepatic steatosis in humans (200).

Low carbohydrate diets have been shown to reduce serum TG and increase HDL-C. In addition,
they promote weight loss and extend beneficial effects on several chronic inflammatory
diseases, including atherosclerosis, diabetes, hypertension, and dyslipidemia (201). Following
a low carbohydrate diet, decreased levels of cholesterol accumulation were observed in
cholesterol challenged animals when compared to the unchallenged group, which may be
attributed to the increased HDL-C concentrations observed in the low carbohydrate group. In
addition, low carbohydrate diets have been shown to decrease levels of inflammatory cytokines
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MCP-1, TNF-α, and IL-2, decrease macrophage infiltration, and increase adipocyte size in
guinea pigs. In addition, low carbohydrate diets were found to decrease levels of ox LDL (202).

The international guidelines reported that lifestyle changes including diet are the only
therapeutic approach recommended for fatty liver. The predictor of changes in liver fat content
found in intervention studies looked to increase adherence to the Mediterranean diet and level
of physical activity (203). The major physiological mechanisms include antioxidant and antiinflammatory effects of the foods included in the Mediterranean dietary pattern (204). The
Mediterranean diet has benefits with regards to decreased cardiovascular diseases and
improved insulin sensitivity because of the high intake of antioxidants. Vegetables are the main
source of phenolic compounds on this diet. Also, polyunsaturated fatty acids of the n-3 series
from fish regulate haemostatic factors that induce protection against a variety of chronic
diseases. Olive oil also represents a high intake of monounsaturated fatty acids and a good
source of phytochemicals (205). Better glycemic indices, with good lipid profile and lower
blood pressure has been correlated with Mediterranean diet. In one study, the Mediterranean
diet had a modest impact on lipid profiles (206).

High consumption of a variety of fruits and vegetables were found to protect against CVD and
development of MetS. The mechanisms of protection may depend on high amount of dietary
fiber, antioxidant vitamins (A, C, and E) and carotenoids (207). Fruit and vegetable
antioxidants, including vitamins and flavonoids, reduce thrombosis, improve endothelial
function and contribute to an anti-inflammatory effect (208). As free radical scavengers,
flavonoids inhibit lipid peroxidation, promote vascular relaxation and prevent atherosclerosis
and other factors associated with the MetS (209).
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Consumption of whole grains (bread, pasta, and rice) is a major characteristic of the
Mediterranean diet found to protect against several metabolic disorders like obesity, diabetes
and CVD by their fiber content which improved insulin sensitivity, positively influencing a
promoter of the process of carcinogenesis such as insulin-like growth factor 1 (IGF-1). Fiber
consumption is also effective in lowering the risk of deteriorating glucose tolerance and
development of type 2 diabetes (210). The preventing chronic disease by fiber present in bran
and germ depends on their bioactive compounds with antioxidant and anti-carcinogenic
properties (minerals, trace elements, vitamins, carotenoids, polyphenols and alkylresorcinols).
Wheat is rich source of methyl donors and lipotropes (methionine, betaine, choline, inositol
and folates) which is involved in cardiovascular and hepatic protection, lipid metabolism and
DNA methylation (211).

Foods which containe oil (fish, nuts, avocado and olives) high in MUFAs have a beneficial
effect on the risk of CVD (212). Fish such as sardine and anchovy have been shown to protect
against CVD due to their content of MUFAs and PUFAs, especially the long-chain n-3 PUFAs.
Olive oil, the main fat source of the Mediterranean diet, exerts its benefits on lipoprotein
metabolism due to the high content of MUFAs (such as oleic acid) and several
microcomponents that have antioxidant activity. In addition, olive oil has a role in cholesterol
regulation; LDL oxidation promoting anti-inflammatory, antithrombotic and antihypertensive
vasodilator effects. Replacing SFA by MUFA affects plasma lipid profile and improves insulin
sensitivity (213).

Moringa oleifera leaves
Moringa, a plant that is a native to parts of Africa and Asia, is the sole genus in the family
Moringaceae. It contains 13 species from tropical and subtropical climates that range in size
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from tiny herbs to massive trees. The most widely cultivated species is Moringa oleifera, a
multipurpose tree native to India (214). Moringa oleifera is the most widely known and
cultivated species native to the foothills of the Himalayas in northwestern India and cultivated
throughout the tropics. Moringa oleifera is grown for its nutritious pods, edible leaves and
flowers and has many useful properties including its use as a source of food, medicine, cosmetic
oil and forage for livestock. It is commonly known by its regional name as drumstick tree. It is
a rapidly growing tree that is widely cultivated and has now become established in Afghanistan,
Florida and East and West Africa. Its height ranges from 5 to 10 meters (214).

Moringa oleifera is an important plant for its contribution in bioactive compounds. Moringa
oleifera leaves, the most used part of the plant, are rich in vitamins, carotenoids, polyphenols,
phenolic acids, flavonoids, alkaloids, glucosinolates, isothiocyanates, tannins and saponins
(215). The high contribution in bioactive compounds might explain the pharmacological
properties of Moringa oleifera leaves. Many studies in vitro and in vivo in animals confirmed
numerous pharmacological properties (215).

Traditional uses
All parts of Moringa oleifera are traditionally used for different purposes, but leaves are
generally the most used in human and animal nutrition and in traditional medicine. Leaves are
rich in protein, minerals, beta-carotene and antioxidant compounds, which are often lacking
among the populations of underdeveloped or developing countries. In traditional medicine,
leaves are used to treat several sicknesses such as malaria, typhoid fever, parasitic diseases,
arthritis, swellings, skin diseases, genito-urinary diseases, hypertension and diabetes (216,
217).
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The different parts of Moringa oleifera including roots, leaves, flowers, fruits and seeds are
also known to be good sources of phytochemical compounds. (214). Therefore, every part of
this plant, including root, bark, gum, leaf, fruit (pods), flowers, seed, and seed oil have been
used for various biological activities, including gastric ulcers (218), antidiabetic effect (219),
hypotensive agent (220) cardiovascular action, liver disease (221) and hepatic and renal
functions (222), regulation of thyroid hormone status (223), protecting against oxidative stress
(224), treatment of inflammation (225), liver protection against hepatotoxic drugs and carbon
tetrachloride (226), reduced cholesterol in the liver and kidney (227, 228, 229), antibacterial
activity (230); anti-cancer (206); and hepatoprotective effects (231).

Vitamins
Fresh leaves of Moringa oleifera contain 11,300–23,000 IU of vitamin A/ 100g of dry matter
(232). Vitamin A participates in many physiological processes such as vision, reproduction,
embryonic growth and development, immune competence, cell differentiation, cell
proliferation and apoptosis, maintenance of epithelial tissue, and brain function (233). Also,
fresh leaves are a good source of carotenoids with pro-vitamin A action. They contain 6.6–6.8
mg/100 g of β-carotene, greater that carrots, pumpkin and apricots (6.9, 3.6 and 2.2 mg/100 g,
respectively) (234).

For vitamin C, fresh leaves contain 200 mg/100 g which is a concentration greater than oranges
(235, 234). These amounts are of interest, as the vitamin C favors the conversion of cholesterol
into bile acids and hence lowers blood cholesterol levels in humans and animals and increases
the absorption of iron in the gut by reducing ferric to ferrous state. Also, Moringa leaves protect
the body from various deleterious effects of free radicals, pollutants and toxins and act as antioxidants (236).
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Moringa oleifera fresh leaves are a good source of vitamin E (α-tocopherol) and contain 9.0
mg/100 g similar to nuts (234). Vitamin E acts as antioxidants, but it is also involved in the
modulation of gene expression and inhibition of cell proliferation (237).

Polyphenols
The dried leaves of Moringa oleifera are a great source of polyphenol compounds such as
flavonoids and phenolic acids.

Flavonoids
Flavonoids are a sub-group of polyphenolic compounds having a benzo-γ-pyrone structure and
they are synthesized in response to microbial infections (238). Epidemiological studies showed
that, high intake of flavonoids has protective effects against many infectious (bacterial and viral
diseases) and degenerative diseases such as cardiovascular diseases, cancers, and other agerelated diseases. Moringa oleifera leaves are a good source of flavonoids (239).

Myricetin, quercetin and kaempferol are the main flavonoids found in Moringa oleifera leaves.
In dried leaves, myricetin concentration is5.804 mg/g of dry weight, while quercetin and
kaempferol concentrations range from 0.207 to 7.57 mg/g of dry weight and not detectable
amounts (ND) to 4.59 mg/g of dry weight, respectively (240, 241, 242).

Quercetin
Quercetin is found in dried Moringa oleifera leaves at concentrations 100 mg/100g as
quercetin-3-O-β-d-glucoside (iso- quercetin or isotrifolin) (243, 244). Quercetin is a strong
antioxidant with multiple therapeutic properties (245). It has antidyslipidemic, hypotensive,
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and anti-diabetic properties in the obese Zucker rat of metabolic syndrome (246). It can reduce
hyperlipidemia and atherosclerosis in high cholesterol or high-fat fed rabbits (247, 248). It can
protect insulin-producing pancreatic β cells from Streptozotocin (STZ) induced oxidative stress
and apoptosis in rats (249).

Phenolic Acids
Phenolic acids are a sub-group of phenolic compounds derived from hydroxybenzoic acid and
hydroxycinnamic acid, naturally present in plants and these compounds have antioxidant, antiinflammatory, antimutagenic and anticancer properties (250, 251). In dried leaves, Gallic acid
is the most abundant, with a concentration of 1.034 mg/g of dry weight. The concentration of
chlorogenic and caffeic acids ranges from 0.018 to 0.489 mg/g of dry weight and ND to 0.409
mg/g of dry weight, respectively (252,253).

Chlorogenic acid
Chlorogenic acid is an ester of dihydrocinnamic acid (caffeic acid) and quinic acid, is a major
phenolic acid in Moringa oleifera leaves (254). Chlorogenic acid has a role in glucose
metabolism. It inhibits glucose-6-phosphate translocase in rat liver, reducing hepatic
gluconeogenesis and glycogenolysis (255). It was found to lower post-prandial blood glucose
(PPBG) in obese Zucker rats (256). In oral glucose tolerance test (OGTT), cholorogenic acid
reduced the glycemic response in both rats and humans; in rodents, it reduced the glucose area
under the curve (257). Its anti-dyslipidemic properties are more evident as it reduces plasma
total cholesterol and TG in obese Zucker rats or HFD mice (258) and reverses streptozotocin induced dyslipidemia in diabetic rats (255).
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Alkaloids
Alkaloids are a group of chemical compounds that contain mostly basic nitrogen atoms. Several
of

these

compounds,

rhamnopyranosyloxy)

such

as

N,α-L-rhamnopyranosyl

phenylacetonitrile

(niazirin),

vincosamide,

pyrrolemarumine

4-(α-L4′′-O-α-L-

rhamnopyranoside, 4′-hydroxy phenylethanamide-α-L-rhamnopyranoside (marumoside A)
and

its

3-O-β-D-glucopyranosyl-derivative

(marumoside

B)

and

methyl

4-(α-L-

rhamnopyranosyloxy)-benzylcarbamate, have been isolated from Moringa oleifera leaves
(259, 260).

Glucosinolates and Isothiocyanates
Glucosinolates are a group of secondary metabolites in plants. Structurally they are β-Sglucosides of thio-oxime-O-sulfates and synthesized from amino acids. 4-O-(α-Lrhamnopyranosyloxy)-benzyl glucosinolate has been identified as the dominant leaf
glucosinolate of Moringa oleifera and is accompanied by lower levels of three isomeric 4-O(α-L-acetylrhamnopyranosyloxy)-benzyl glucosinolates, which reflect the three position of the
acetyl group at the rhamnose moiety of the molecule In young and older leaves which have
around 116 and 63 mg/g of dry weight, respectively (261). Both glucosinolates and
isothiocyanates are important in health promoting and prevention of disease (262).

Tannins
Tannins are water-soluble phenolic compounds that precipitate alkaloids, gelatin and other
proteins. Their concentrations in dried leaves range between 13.2 and 20.6g tannin/kg (263)
and in freeze-dried leaves between 5.0 and 12.0 g tannin/kg (264). They have different
biological properties: anti-cancer, antiatherosclerotic, anti-inflammatory, anti-hepatoxic,
antibacterial and anti-HIV replication activity (265).
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Saponins
Saponins are a group of natural compounds that consist of an isoprenoidal-derived aglycone,
designated genin or sapogenin, covalently linked to one or more sugar moieties (266). Moringa
oleifera leaves are a good source of saponins. Their concentration in dried leaves is
approximately 50 g/kg of dry weight, while in freeze-dried leaves it ranges between 64 and 81
g/kg of dry weight (267). Saponins have anti-cancer properties (268).

Pharmacology
Hypolipidemic effects
Many bioactive compounds found in Moringa oleifera leaves may influence lipid homeostasis.
Phenolic compounds as well as, flavonoids, have important roles on lipid regulation (269).
They are involved in the inhibition of pancreatic cholesterol esterase activity thereby reducing
and delaying the cholesterol absorption, and binding bile acids by forming insoluble complexes
and increasing their fecal excretion thereby decreasing plasma cholesterol concentrations
(270). The extracts of Moringa showed antihyperlipidemic activity due to inhibition of lipase
and cholesterol esterase thus showing its potential for prevention/treatment of hyperlipidemia
(271).

Moringa oleifera has strong effect on lipid profile through cholesterol reducing effect.
Cholesterol homeostasis is maintained by the two processes, cholesterol biosynthesis in which
HMG-Co-A reductase catalyzes rate limiting process and cholesterol absorption of both dietary
cholesterol and cholesterol cleared from the liver through biliary secretion. The HMG-CoA/mevalonate ratio has an inverse relationship to the activity HMG-Co-A reductase (272). The
activity of this enzyme was depressed by the ethanolic extract of Moringa oleifera supporting
its hypolipidemic action.

40

Moringa leaves also contain bioactive phytoconstituent, (β-sitosterol) with cholesterol
lowering effect. Cholesterol lowering action in the serum of high fat diet fed rats which might
be attributed to the presence of bioactive Phyto-constituents, i.e. β- sitosterol (227).

Saponins found in Moringa leaves lowered cholesterol by preventing its absorption through
binding with cholesterol in the intestinal lumen, and/or by binding with bile acids, causing a
reduction in the enterohepatic circulation of bile acids and increasing their fecal excretion. The
increased bile acid excretion is offset by enhanced bile acid synthesis from cholesterol in the
liver and consequent lowering of the plasma cholesterol (219).

Antioxidant effects
Moringa leaves are a good source of natural antioxidant due to the presence of antioxidant
compounds such as ascorbic acid, alkaloids, flavonoids, glycosides, phenolics, saponins,
steroids, and tannins and carotenoids (224, 273,274), which are used in patients with
inflammatory conditions, cancer, hypertension, and cardiovascular diseases (227, 275).

The beta carotene found in Moringa leaves acts as antioxidants. The antioxidants have the
maximum effect on the damage causing free radicals, only when it is ingested in combination
with nutrients and a group of antioxidants. A combination of antioxidants found in Moringa
leaves was more effective than a single antioxidant due to antioxidant cascade mechanism (276,
232, 277).

The extract of Moringa leaves contain tannin, saponin, flavonoids, terpenoids and glycosides,
which have medicinal properties. These compounds have been shown to be effective antioxidants, antimicrobial and anti-carcinogenic agents (278). Phenolic compounds act as primary
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antioxidants (279). They inactivate lipid free radicals or prevent decomposition of
hydroperoxides into free radicals due to their redox properties, which play an important role in
adsorbing and neutralizing free radicals, quenching singlet or triplet oxygen, or decomposing
peroxides (280, 281).

The radical scavenging and antioxidant activities of the aqueous and aqueous ethanol extracts
of freeze-dried leaves of Moringa oleifera from different agro-climatic regions were
investigated by Siddhuraju and Becker (282). They found that, different leaves extracts
inhibited 89.7%–92.0% peroxidation of linoleic acid and had a scavenging activity on
superoxide radicals in a dose-dependent manner in the beta-carotene-linoleic acid system. Iqbal
and Bhanger (283) showed that, the environmental temperature and soil properties have
significant effects on antioxidant activity of Moringa oleifera leaves.

Anti-Inflammatory and Immunomodulatory effect
The extract of Moringa oleifera leaves inhibited human macrophage cytokine production
(TNF-α, IL-6 and IL-8) induced by extract of cigarette smoke and by LPS, similar to aspirin
(284). Also, Waterman et al. (285) found that both Moringa oleifera concentrate and
isothiocyanates isolated from the leaves significantly decreased gene expression and
production of inflammatory markers in RAW macrophages.

The extracts of Moringa oleifera leaves stimulated both cellular and humoral immune response
in cyclophosphamide-induced immunodeficient mice through increases in white blood cells,
percent of neutrophils and serum immunoglobulins (286,287). In an animal model (mice), the
anti-inflammatory and immunomodulatory effects of Moringa oleifera leaves were
investigated in vitro and in vivo. Many bioactive compounds which are involved in the anti-
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inflammatory process such as quercetin showed to inhibit activation of NF-kB and also the
subsequent NF-kB-dependent downstream events and inflammation (288). In addition,
flavonoids and phenolic acids were involved in the anti-inflammatory process (287).

Hepato-protective effects
Albino rats were treated with aqueous and alcoholic extract of Moringa (200mg/kg/day) for 7
days. Liver function was assessed based on liver to body weight ratio, SGPT, SGOT, ALP and
bilirubin. They found that methanol extract of M. oleifera leaf have hepatoprotective effects in
rats. Also, Moringa roots and flowers are reported to have hepatoprotective activity. In
addition, aqueous and alcohol extracts of Moringa roots and flowers were found to have a
significant hepatoprotective effect, which might be due to the presence of quercetin (224, 277).
Moringa leaves have a substantial effect on the levels of SGOT, AST, SGPT, ALT, ALP and
bilirubin in the serum; lipids, and lipid peroxidation levels in liver of rats (227).

In animals treated with the extract of Moringa oleifera leaves, a reduction of serum ALT, AST,
ALP and BUN and creatinine was reported (289, 290). These findings were confirmed by
histological examinations, which revealed an amelioration of hepatic and kidney damages
induced by drugs. Similar results were found in rats co-treated with Moringa oleifera leaves
and NiSO4 in order to induce nephrotoxicity (291). Also, Das et al. (288) suggested a potential
role of the leaves in the prevention of NAFLD due to a reduction of ALT, AST and ALP and
a lower liver damage in rats fed with high fat diet and co-treated with Moringa oleifera leaves.
Also, the administration of the extract of Moringa oleifera leaves in mice was followed by
decrease in serum ALT, AST, ALP, BU) and creatinine (292,293).
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Anti-hyperglycemic (Antidiabetic) effect
Many compounds found in Moringa oleifera leaves might be involved in glucose homeostasis.
For example, isothiocyanates have been reported to reduce insulin resistance and hepatic
gluconeogenesis (294). Also, polyphenol compounds such as phenolic acids and flavonoids
have effects on glucose homeostasis. These compounds have anti-diabetic effects through
influencing β-cell mass and function, as well as energy metabolism and insulin sensitivity in
peripheral tissues. Their effects might be due to antioxidant, enzyme inhibition, receptor
agonist or antagonist activity (295, 296). Phenolic compounds, flavonoids and tannins are
reported to inhibit intestinal sucrase and, slightly, pancreatic α-amylase actions (270).

The beneficial activities of Moringa oleifera leaves on carbohydrate metabolism have been
shown by different mechanisms including preventing and restoring the integrity and function
of β-cells, increasing insulin activity, improving glucose uptake and utilization (271).
Hypoglycemic and antihyperglycemic activity of the leaves of M. oleifera might be due to the
presence of terpenoids, which are involved in the stimulation of β-cells and the subsequent
secretion of insulin. Also, flavonoids have been shown to play an important role in the
hypoglycemic action (297).

Hypotensive effect
Moringa leaves contain several bioactive compounds which have been used for stabilizing
blood pressure. Moringa leaves contain nitrile, mustard oil glycosides and thiocarbamate
glycosides which have been shown to lower blood pressure. The isolated four pure compounds,
niazinin A, niazinin B, niazimicin and niazinin A + B from ethanol extract of Moringa leaves
showed a blood pressure lowering effect in rats mediated possibly through a calcium antagonist
effect (224, 298).
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Effects on ocular diseases
The major cause of blindness, which ranges from impaired dark adaptation to night blindness,
is vitamin A deficiency. Moringa leaves, pods and leaf powder contain high concentration of
vitamin A, which can help to prevent night blindness and eye problems. Also, consumption of
leaves with oils improved vitamin A nutrition and delayed development of cataract (227).

Anticancer effects
The capacity of Moringa oleifera leaves to protect organisms and cells from oxidative DNA
damage associated with cancer and degenerative diseases was reported in different studies
(299). Khalafalla et al. (301) found that the extract of Moringa oleifera leaves inhibited the
viability of acute myeloid leukemia, acute lymphoblastic leukemia and hepatocellular
carcinoma cells. The presence of several bioactive compounds, such as 4-(α-L-rhamnosyloxy)
benzyl isothiocyanate, niazimicin and β-sitosterol-3-O-β-D-glucopyranoside suggested the
potential anti-cancer properties of Moringa oleifera leaves (302).
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Experimental Design
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3.1 Background
Hypercholesterolemia is defined as high plasma cholesterol levels, and is a risk factor for many
cardiovascular events. Total cholesterol levels above 200 mg/dl is considered an independent
risk factor for development of peripheral vascular and coronary artery disease (CAD), and
considerable attention has been directed toward cholesterol lowering therapies and alternative
interventions for improving vascular function (1).

Several studies suggested that high doses of dietary cholesterol are a critical factor in the
development of experimental steatohepatitis in animal models (2-5). Also, human studies
support the hypothesis that dietary cholesterol plays a role in the development of steatohepatitis
(6). In an epidemiological study, it was found that dietary cholesterol consumption was
independently associated with the development of cirrhosis (6).

Moringa leaves extract and fraction has been shown to decrease hypertriglyceridemia and
hypercholesterolemia. The anti-hypelipidemic effect might

be due to decreased

cholesterogenesis and fatty acid synthesis via inhibition of pancreatic cholesterol esterase
(limiting the absorption of dietary cholesterol) and pancreatic lipase (involved in the inhibition
of dietary triglyceride absorption) (7,8).

Phenolic compounds which are found in MO leaves have an important role in stabilizing lipid
oxidation and are associated with antioxidant activity due to their scavenging ability because
of their hydroxyl groups (9). Although the phenolic compounds are considered to be the major
phytochemicals responsible for antioxidant activity of MO leaves, Moringa is also a good
source of ascorbic acid which has antioxidant activity (10, 11).The antioxidant bioactive
compounds found in MO leaves indicate scavenging activity due to hydrogen proton donation
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(12). The beneficial effects of flavonoids present in MO leaves are due to their antioxidant
properties. The mechanism of antioxidant action has been shown to decrease the formation of
reactive oxygen species via suppression of enzymes or chelating trace elements involved in
free-radical production, scavenging reactive species, protecting antioxidant defenses,
decreasing alphatocopherol radicals, and activating antioxidant enzymes (13, 14).

According to Lako et al., (15), quercetin of dried MO leaves is present in concentrations as
high as 100 mg/100 g. Quercetin is a good antioxidant with many therapeutic properties (16,
17). Quercitin has showed anti-dyslipidemic, hypotensive, and anti-diabetic effects in the obese
rat model of metabolic syndrome (18). Rajanandhet al. (19) investigated the anti-inflammatory
effects of MO leaves extract in rats fed with an atherogenic diet in order to induce
hyperlipidemia. They showed that, TNF-α and IL-1 in the serum was significantly lower in rats
treated with extract of MO leaves compared to control. The effect of supplementation of MO
leaves concentrate in obese-induced mice with very high-fat diet was tested. A reduction of
gene expression of pro-inflammatory markers, TNFα, IL-6 and IL-1β in the liver and ileum
was found in tissues in mice treated with Moringa oleifera concentrate compared to the control
group (20).

In these studies, we aim to investigate the protective effects of the bioactive components of
MO leaves in protecting against hepatic steatosis.

3.2 Experimental diets
Isocaloric diets were formulated to meet the nutritional requirements of guinea pigs. Dietary
cholesterol at 0.25% in this model corresponds to an fed amount equal to 2,500 mg/d in a
human diet (21).
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This project required the formulation of three different experimental diets:
(A) Control: a pelleted non-purified diet that met all the nutritional requirements for guinea
pigs plus 0.25% of dietary cholesterol (w/w of diet), which is sufficient to ensure liver
damage in the proposed time frame of the experiment (6 weeks) (22).
(B) Low Moringa (LM): a pelleted non-purified diet that was matched to the control taking
into consideration the addition of 10% powdered MO leaves to adjust macronutrient
intake (equivalent to 22g Moringa leaves/kg body weight of human).
(C) High Moringa (HM): a non-purified diet matched to control taking into consideration
the addition of 15% powdered MO leaves to adjust macronutrient intake (equivalent to
33g Moringa leaves/kg body weight of human).
All ingredients were homogeneously mixed with water (5% by weight), and pelleted via cold
extrusion process for all diets. After that, diets were dried at 88-92°F for 2 days to remove
excess water. The composition of the MO leaves and experimental diets are presented in Table
3.1 and Table 3.2, respectively.

3.3 Animals
For this project, we used the guinea pigs model challenged with cholesterol, which has been
shown to mimic humans in hepatic cholesterol and lipoprotein metabolism (23).

Twenty-four male Hartley guinea pigs weighing between 200 to 300 grams (6 weeks old) were
housed in pairs in a light cycle room for a total of 12 cages. During the first week of acclimation,
the animals received regular chow ad libitum and had free access to water. After one week, the
cages were randomly assigned to either one of three experimental diets named "Control", "Low
Moringa" (LM) (10%) and high Moringa (HM) (15 %) for a total of four cages per group.
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Food consumption was monitored three times a week, weighing the food left on the feeder and
subtracting that from the amount given two days prior. Once a week, guinea pigs were weighed
and their body weight was monitored to ensure proper growth and health.

After 6 weeks, guinea pigs were fasted for 12 hours and anesthetized with isoflurane. Animals
were sacrificed using the heart puncture technique. Blood from the heart was collected and
centrifuged immediately (2000xg) to separate the plasma. Liver, heart and adipose tissue
(epididymal tissue) were collected and preserved at -80° C for further analysis.

All animal experiments were performed in accordance with U.S. Public Health Service/ U.S.
Department of Agriculture guidelines. Experimental protocols were approved by the
University of Connecticut IACUC (Protocol number A16-003).

Food intake and bodyweight
During the intervention, the guinea pigs consumed an average of 20.7 and 23.6 grams of food
per day, in the 10 and 15% Moringa groups, respectively, (which is equivalent to 2.07 and 3.54
gm of MO leaves/day) compared to 24.0 grams for control group. There were no differences in
food intake, caloric intake, weight gain or final body weight among groups during the
intervention in the control, 10 and 15% Moringa groups, respectively (Table 3.3).

Liver and adipose tissue
There was no difference in weights of liver or epididymal adipose tissue in the control, 10 and
15% Moringa groups, respectively during the intervention. Data are shown in Table 3.3.
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3.4 Discussion
The use of suitable animal models is essential to understand the mechanisms by which Moringa
affects plasma and hepatic lipids. The similarity between guinea pigs and humans in terms of
lipoprotein and hepatic cholesterol metabolism is due to: 1) higher concentrations of free
compared to esterified cholesterol in the liver (24); 2) guinea pigs have plasma cholesteryl
ester transfer protein (CETP) activity (25), a critical component for human reverse cholesterol
transport (26) and lecithin: cholesterol acyltransferase (LCAT) (27), and lipoprotein lipase (28)
activities that contribute to remodeling of plasma lipoproteins; 3) guinea pigs exhibit moderate
rates of hepatic cholesterol synthesis and catabolism (29,30); 4) there is no Apo B mRNA
editing in liver (31); 5) guinea pigs require dietary vitamin C, an important anti-oxidant that
may play a role in oxidation and atherosclerosis (32). 6) guinea pigs respond to dietary fat
saturation, dietary cholesterol, dietary fiber by alterations in LDL cholesterol (30); 7) guinea
pigs are good models for studying the mechanisms by which statins, and other drugs lower
plasma LDL cholesterol (33).

No significant difference was observed between groups in food intake and body weight in the
present study. Similar to our results, Ghebreselassie et al. (34) reported that, there was no
significant change in body weight of mice treated with doses of 600 and 750 mg/kg of Moringa
extract. In addition, no significant change in weight of liver and kidney was observed in all
animals. This might suggest a non-toxic effect of the Moringa extract. In contrast, lower food
intake has been found in rats treated with MO leaves extract when compared to the group feed
with only high-fat diet (35). Therefore, the body weight gain in these groups was significantly
lower than the rats feed with only high-fat diet. However, in our study there were no differences
in body weight associated with Moringa intake.
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3.5 Strengths and limitations
Strengths of this study design include the use of an animal model that has similar cholesterol
metabolism to humans (36). The guinea pigs size also facilitates the sacrifice process and tissue
collection. Guinea pigs have been used numerous times to evaluate the effects of cholesterol,
dietary fat, polyphenols and carotenoids among others on various measures of health (37, 38,
39). Another strength is that the Moringa oleifera leaves used in this study were added to the
food preparations similar to what humans do in their diet (40, 41).

The main limitation of the study design was the lack of analyses of the bioactive components
of MO leaves although the concentrations most commonly found have been reported in other
studies (15, 42)
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Tables
Table 3.1 Composition of dried Moringa oleifera leaves1
Component (g)

g/100g

Carbohydrate2

30

Fiber

44

Protein

5

Fat

3

Moisture

10

Minerals

8

Quercetin (41)3

0.0207

Chlorogenic acid (41)3

0.049

1

Proximate analysis of Moringa were made by CIAD (Centro de Investigation en Alimentos
Desarrollo (Hermosillo, Mexico)
2
2 g sugar and 28 g starch
3
Chlorogenic acid and quercetin values were taken from the literature
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Table 3.2 Composition of Experimental Diets1,2
Component

Control
g/100 g

Soy Protein

22

Low Moringa (10%)

% Energy
23

Moringa Protein
Carbohydrate3

41

41.9

Carbohydrate
from Moringa
Fat4

15.1

35.1

Moringa fat

g/100 g

High Moringa (15%)

% Energy g/100 g

% Energy

21.5

22.5

21.2

0.5

0.5

0.8

38

38.8

36,5

3

3.1

4.5

14.8

34.4

14.7

0.3

0.6

0.45

35.1

23

41.9

Vitamins4

1.1

-

1.1

-

1.1

-

Minerals4

8.1

-

7.3

-

7.1

-

0.8

Moringa Minerals
Cellulose

10

-

8.1

1.0
-

4.4

Moringa fiber

5.9

-

6.6

Guar Gum

2.5

-

0

-

0

-

Cholesterol

0.25

-

0.25

-

0.25

-

Energy Density
(Kcal/g)

3.87

3.87

1

3.87

Moringa leaves were provided by Scientech Health International S.A de CV (Mexico City,
Mexico).
2
Percent energy from macronutrients is the same for all diets
3
Mixture of starch/sucrose
4
Fat mix was -palm kernel: oil: olive oil: safflower oil (50:25:25), high in lauric and myristic
acids
5
Compostion of vitamin and mineral mixes were formulated according to guinea pig
requirements.
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Table 3.3 Food intake, initial body weight, weight gain, final body weight, liver and
adipose tissue weights of guinea pigs fed a hypercholesterolemic diet with no Moringa
(Control), Low Moringa (LM) or High Moringa (HM)1
Parameter

Control

Low Moringa

High Moringa

24.0±2.3

20.7±7.8

23.6±2.9

Energy intake (Kcal)

92±9

81±30

91±11

Initial body weight (g)

334±15

315±13

339±17

Final body weight (g)

535±44

543±55

507±43

Weight gain (g)

201± 49

229±49

167±49

Liver weight (g)

27.9±3.0

28.4±5.2

25.5±3.9

Adipose weight (g)

55.9±13.9

53.6±24.7

59.5±18.9

Food Intake (g)

Heart weight (g)
1

2.3±0.5

2.4±0.3

Values are expressed as mean ± SD for n = 8 guinea pigs per group.
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2.3±0.5
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Chapter 4
Effects of Moringa oleifera leaves on plasma lipids,
lipoprotein subfractions and size and on parameters of
reverse cholesterol transport
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4.1 Background
The liver plays a pivotal role in lipid metabolism. It extracts cholesterol from intestinal
chylomicrons and excretes it back into the intestines with bile acids. It biosynthesizes TG and
cholesterol and packages them as VLDL, that is secreted into the bloodstream. Through the
LDL receptor (LDLR), plasma LDL as well as IDL or VLDL are removed from circulation.
HDL mediates the reverse transport of cholesterol from extra-hepatic tissues to the liver (1).
Lipoprotein metabolism is important because disturbances in the lipoprotein profiles are
considered a risk factor for many chronic diseases such as cardiovascular disease, metabolic
syndrome, NAFLD and type 2 diabetes mellitus (T2DM) (2). Guinea pigs have been shown to
be a suitable animal model for evaluating lipoprotein profile altered by cholesterol challenges;
their cholesterol metabolism is similar to the human situation making them ideal models to
understand alterations of metabolic pathways caused by dietary interventions (3, 4, 5).

Moringa leaves have been shown to have hepatoprotective activity and decrease lipid profile
in the serum of high-fat diet fed rats which may be attributed to the presence of β – sitosterol
(6, 7). The aqueous extract of Moringa leaves has been found to lower the blood sugar and
inhibit the growth of pathogenic microorganisms in diabetic rats (8, 9). In addition, flavonoids
and saponins lower cholesterol absorption by the inhibition of cholesterol micellar solubility,
thus, these bioactive compounds found in aqueous extract have hypolipidemic effects (10).
Chumark et al. (11) examined the therapeutic potential of Moringa oleifera leaves on
dyslipidemia induced in rabbits on a high- cholesterol (5%) diet (HCD) for 12 weeks. By the
end of the regimen, relative to rabbits on a normal diet, HCD-fed rabbits experienced severalfold increases in the plasma levels of total cholesterol (TC), HDL-C, LDL-C, and TG. When
these HCD rabbits were concomitantly fed a M. oleifera aqueous leaf extract, at the daily dose
of 100mg/kg-BW for the duration of the protocol, these increases were reduced: for TC and
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lipoprotein-cholesterol by about 50%, for TG by 75%. The anti-dyslipidemic effects of MO
leaves were also examined in rats fed a high-fat diet (HFD) containing 16% fat, with or without
an aqueous extract of Moringa leaves for 30 days. In treated rats, the plasma total cholesterol
(TC) was reduced (12). In another study, Jain et al. (13) fed albino rats for 30 days, a diet
contained 26% fat, with or without a methanolic extracts of Moringa oleifera leaves. At the
highest dose (600 mg/kg-BW), Moringa oleifera leaves treatment reduced plasma TC, LDLC, VLDL-C, and TG. Interestingly, serum HDL-C was unchanged by HFD diet alone;
however, HDL-C was increased in rats fed leaf extract-supplemented HFD, significantly
reducing the TC/HDL-C ratio. Flavonoids and saponins present in the leaves of Moringa
oleifera are reported to increased HDL-C concentration and decrease LDL and VLDL
cholesterol in hypercholesteremic rats (14). Polyphenols can protect LDL from oxidation
through inhibition of lipid peroxidation by acting as chain breaking peroxyl radical scavengers
and also inhibit hepatic lipid synthesis (15, 16).

Therefore, these studies suggest that MO leaves can alter plasma lipids and lipoprotein
metabolism. Based on these data, we hypothesized that Moringa leaves would decrease plasma
total cholesterol, LDL cholesterol and triglycerides in guinea pigs fed a high cholesterol diet
for 6 weeks.

4. 2 Materials and Methods
4.2.1 Plasma Lipids
Plasma HDL-C, TC, LDL-C, total triglycerides and glucose were measured with direct
enzymatic reactions and photometric detection using the Cobas c111 analyzer (Roche
Diagnostics). LDL cholesterol was calculated by the Friedwald equation as previously reported
(3).
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4.2.2 Plasma insulin
To measure plasma insulin, a Rat/Mouse Insulin kit (Crystal Chem. Dowers, Grove, IL), which
was found to cross-react with guinea pig insulin was used for this assay. 5 µl of plasma were
used for this assay. The standard curve consisted of concentrations ranging from 0.156 to 10
ng/mL. The CV for this assay was 10%.

4.2.3 Lipoprotein size and number
Lipoprotein size and number were measured by nuclear magnetic resonance (NMR)
spectroscopy. This technique can quantify the size and concentration (“number”) of lipoprotein
particles expressed each as an average particle size or as lipoprotein particle concentration (17,
18) and calculate the cholesterol contained in lipoproteins. (19). Each lipoprotein subclass
signal emanates from the aggregate number of terminal methyl groups on the lipids contained
within the particle, with the cholesteryl esters and triglycerides in the particle core each
contributing three methyl groups, and the phospholipids and unesterified cholesterol in the
surface shell each contributing two methyl groups. Because the methyl signals from these lipids
are indistinguishable from each other, they overlap to produce a bulk lipid particle signal (20).
The amplitude of each lipoprotein subclass signal serves as a measure of the particle
concentration of that subclass (21). The NMR LipoProfile test is a diagnostic tool used to
identify and manage risk for lipid-related heart disease (19, 20). Samples were analyzed for
lipoprotein size and number at LipoScience Inc (Raleigh, NC)

4.2.4 LCAT and CETP activities
LCAT activity was determined by use of a commercially available fluorometric assay kit (Cell
Biolabs Inc., San Diego, CA). The relative LCAT activity was assessed by the strength of the
fluorescence signal following an incubation period. CETP activity was measured by use of a
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commercially available assay kit (BioVision Inc., Milpitas, CA). The decrease in fluorescence
intensity over time was used to calculate CETP activity after incubation of plasma with a selfquenching donor molecule acceptor molecule as previously reported by DiMarco et al (22).

4.2.5 Ox LDL
Plasma ox LDL were analyzed using a mouse competitive ELISA (Mercodia, Uppsala,
Sweden) which is based in the mouse monoclonal antibody 4E6, which is directed against a
conformational epitope in oxidized ApoB-100. We have successfully used this method to
measure ox LDL in guinea pigs (23).

4.2.6 Statistical Analysis
Differences between groups were analyzed by one-way ANOVA and LSD post hoc analysis.
P < 0.05 was considered to be significant. All analyses were conducted on SPSS for Windows,
Version 20 (IBM Corp.). All data are presented as mean ± SD.

4.3 Results
4.3.1 Plasma lipids and glucose
There were no differences in plasma total cholesterol, VLDL, LDL, HDL, triglycerides,
glucose or insulin among the control, low moringa or high moringa groups (Table 4.1).

4.3.2 Lipoprotein size and subfractions
Total VLDL or total LDL and all subfractions (large, medium and small) were not different
between groups. Regarding HDL, total HDL, large and small HDL were not affected, while
medium HDL was lower in both groups of moringa compared to control group (P<0.05). There
were no differences in VLDL, LDL or HDL size among groups (Table 4.2).
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4.3.3 LCAT and CETP activity
LCAT activity was higher in both groups of moringa compared to the control group (P<0.05)
(Table 5). In addition, no differences were found in CETP activity or in the concentration of
oxidized LDL between groups (Table 4.3).

4.4 Discussion
4.4.1 Plasma lipids and lipoproteins
Unexpectedly, no changes in plasma lipids, glucose or insulin were observed among groups. It
is well known that Moringa oleifera leaves contain 24.3% of fiber (24), thus we were expecting
to observe decreases in plasma cholesterol due to fiber intake. However, we observed no
changes in plasma total or LDL cholesterol suggesting that the fiber present in Moringa did not
disrupt micelle formation or cause interruption of the enterohepatic circulation of bile acids as
we have observed in other guinea pig studies (25).

Moringa leaves, however, resulted in lower concentrations of the medium HDL particles,
which have been shown to decrease reverse cholesterol transport (RCT) (1). In other study
conducted with low carbohydrate diets observed significant increases in HDL cholesterol,
while medium HDL decreases (26).

4.4.2 LCAT and CETP activities
To further confirm that RCT might have been enhanced by Moringa leaves, we observed higher
LCAT activity. LCAT activity was increased by 55% (p< 0.05) by ML intake while CETP
activity was not different among groups. These results suggest a potential role of ML in
modulating RCT. The key function of lecithin-cholesterol acyltransferase (LCAT) is to form
cholesteryl ester and, at a constant apoA-I concentration, larger discoidal HDL particles are the
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preferred substrate (27). The lipid transfer proteins, cholesteryl ester transfer protein (CETP)
are involved in moving cholesteryl ester, triacylglycerol and phospholipid molecules among
HDL and other lipoprotein particles (28, 29). In one study, over-expression of LCAT increased
HDL-C, but this elevation in HDL-C did not increase RCT from macrophages to feces (30).
An explanation for this observation is that increased esterification by LCAT resulted in an
increase in the production of mature HDL particles and a reduction in lipid-poor preβ-HDL.
Thus, the level of LCAT activity determines the array of HDL particles present in the plasma,
and this in turn influences the efficiency of the various efflux pathways in the removal of cell
cholesterol. In addition, liver expression of CETP promotes macrophage RCT and this effect
is dependent on the LDL receptor (30). Thus although we did not observe changes in
atherogenic lipoproteins, the observed changes in these mediators (LCAT, and HDL size) of
RCT suggest that Moringa may also protect against atherosclerosis. Further studies are
necessary to confirm this theory.

However, there was no difference in oxidized LDL in plasma of guinea pigs consuming
moringa leaves or control diets suggesting that that Moringa leaves do not exert an antioxidant
effect in plasma in these animals that also did not change the concentrations of plasma lipids
due to Moringa treatment

4.5 Conclusion
Although Moringa leaves had no effect on the dyslipidemias induced by the high cholesterol
diets in guinea pigs, Moringa appeared to affect HDL metabolism by decreasing the medium
HDL, which has been considered a less protective HDL and by increasing LCAT activity.
These results suggested a potential role of Moringa leaves in modulating the parameters
involved in RCT.
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Tables
Table 4.1 Plasma lipid profile, glucose and insulin of guinea pigs fed a
hypercholesterolemic diet with no Moringa (control), Low (10%), or High Moringa
(15%)1

Parameter
Total cholesterol

Control
294.6 ± 167.0

Low Moringa
192.9 ± 84.7

High Moringa
251.6 ± 70.3

11.0 ± 2.9

10.6 ± 5.0

11.9 ± 4.0

244.5 ± 166.4

155.0 ± 73.9

187.7 ± 73.4

39.1 ± 28.3

27.4 ± 24.2

52.0 ± 30.3

Triglycerides (mg/dL)

55.9 ± 13.9

53.6 ± 24.7

59.5 ± 18.9

Plasma Glucose

158.4 ± 16.5

154.4 ± 23.4

164.6 ± 18.9

32.4 ± 13.9

34.0 ± 10.7

30.3 ± 11.0

(mg/dL)
VLDL cholesterol
(mg/dL)
LDL cholesterol
(mg/dL)
HDL cholesterol
(mg/dL)

(mg/dL)
Insulin (µU/ml)

1

Values are means ± SD, n=8. Values in the same row with different superscripts are

significantly different at P<0.05
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Table 4.2 Lipoprotein subfractions in guinea pigs fed a hypercholesterolemic diet (0.25
g/100 g) with no Moringa (control), Low (10%), or High Moringa (15%)1
(nmol/l)
Total VLDL
(nmol/L)

Control

Low Moringa

High Moringa

55.2 ±1 28.1

45.4 ± 21.4

61.5 ± 1.7

Large VLDL
(nmol/L)

1.7 ± 1.3

1.1 ± 0.9

1.1 ± 0.9

Medium VLDL
(nmol/L)

14.3 ± 7.0

13.7 ± 7.6

16.7 ± 7.2

Small VLDL
(nmol/L)

39.1 ± 21.2

30.6 ± 14.0

16.7 ± 7.2

531 ± 219

563 ± 173

709 ± 284

IDL
(nmol/L)

63 ± 31

80 ± 33

107 ± 52

Large LDL
(23-30 nm)

148 ± 61

102 ± 46

104 ± 30

Small LDL
(18-23 mn)

320 ± 160

382 ± 123

498 ± 252

1.5±0.6

0.9 ± 0.7

1.5 ± 0.5

Large HDL
(10-13 nm)

0.19±0.13

0.14±0.09

0.21±0.08

Medium HDL
(8.2- 10)

0.56± 0.55a

0.11±0.21b

0.21±0.13b

0.8±0.6

0.6±0.7

1.0±0.5

VLDL size (nm)

51.0 ± 5.7

46.4 ± 5.5

47.4 ± 5.5

LDL size (nm)

20.8 ± 0.6

20.3 ± 0.5

20.3 ± 0.7

HDL size (nm)

9.5 ± 1.0

10.1 ± 0.7

9.7 ± 0.5

Total LDL
(nmol/L)

Total HDL
(µmol/L)

Small HDL
(7.3-8.2)

1

Values are means ± SD, n=8; Means in the same row without a common letter differ at P<0.05
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Table 4.3 Lecithin Cholesterol Acyltransferase (LCAT), Cholesteryl ester transfer
protein (CETP) activity and Oxidized LDL

LCAT activity
(Fluoresence, RFU)
CETP Activity (pmol/L/h)
Oxidized LDL (mg/L)
1

Control

Low Moringa

High Moringa

195.4 ± 46.8a

243.6 ± 34.2b

237.5 ± 20.3b

19.4 ± 13.7

10.8 ±3.8

14.1 ± 12.2

3.9 ± 4.8

2.4 ± 3.5

7.1 ± 3.5

Values are means ± SD, n=8; Values in the same row with different superscripts are

significantly different at P<0.05
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Chapter 5
The effects of Moringa leaves on hepatic steatosis
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5.1 Background
Hepatic steatosis is defined by triglyceride accumulation in hepatocytes as a result of an
imbalance between the uptake of fat and its oxidation and export. The most consistent
underlying pathogenic factor is insulin resistance, which predisposes to lipolysis of peripheral
fat with mobilization to and uptake of fatty acids by the liver (1,2). The pathogenesis of hepatic
triglyceride accumulation is that obesity and insulin resistance increase the release of free fatty
acids (FFA) from adipocytes through increased hormone-sensitive lipase activity (2).
Triglyceride accumulation in hepatocytes increases the vulnerability of the liver to secondary
insults through effects of cytokines or oxidative stress (3) since the circulating FFA is not only
substrate for triglyceride synthesis but may also be directly cytotoxic. The apoptosis of
hepatocytes correlates with progressive inflammation (steatohepatitis), fibrosis, cirrhosis and
hepatocellular carcinoma (4, 5). As stated previously, cholesterol feeding could induce
dyslipidemia and insulin resistance. In animal models an excess of dietary cholesterol also
appears to be an important risk factor for hepatic steatosis and progression to steatohepatitis
(3). ALT and AST are enzymes involved in amino acid metabolism and can be used as
indicators of liver damage (6). Other studies have also shown reduction of serum ALT and
AST in animals treated with the extract of Moringa leaves (7). Pari and Kumar (8) found a
reduction of ASP and AST with Moringa intake and histological evaluation of liver further
documented a recovery from liver damage with Moringa leaves. These results suggest that
Moringa leaves exert protective effects in liver without inducing toxicity. Also, Das et al. (9)
reported a reduction of ALT, AST and ALP and a lower liver damage in rats fed with high fat
diet and co-treated with MO leaves, suggesting a potential role of the leaves in the prevention
of NAFLD. The hepatoprotective effect may be related to antioxidant properties and antiinflammatory effects (10).
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Previous studies showed that a cholesterol challenge leads to hepatic steatosis in animal models
(11) and reported that Moringa decreased lipid profile of liver, heart and aorta in
hypercholesteremic rabbits and increased the excretion of fecal cholesterol (12,13). This
hepatoprotective activity of Moringa has been found in different studies. Ethanolic extracts of
Moringa leaves have shown a protective effect against drug-induced liver damage in rats (8).
Further, histological examinations confirmed an amelioration of the hepatic damages induced
by drugs (14). Moringa leaves also showed the ability to reduce carbon tetrachloride-induced
liver fibrosis and control the rise of serum amino transferase activities and globulin level (10).
In addition, Moringa showed to protect liver exposed to ionizing radiation by increased
antioxidant enzymes and inhibited translocation of nuclear factor kB (NF-kB) from cytoplasm
to the nucleus (15).

Phenolic acids, including chlorogenic acid (CGA), from Moringa leaves have been shown to
have antioxidant, anti-inflammatory and anti-hyperglycemic properties (16). CGA from other
dietary sources has been recognized as an important modulator of metabolic pathways related
to lipid synthesis, lipoprotein uptake and inflammation. It has been reported that CGA
markedly decreased the concentration of TC and TG in plasma and liver, which is most
probably due to the increase of the fatty acid utilization in the liver and the alteration of the
activities of enzymes involved in lipid metabolism (17, 18, 19, 20, 21). Gebhardt (22)
demonstrated that CGA can indirectly yet efficiently inhibit 𝛽-hydroxy-𝛽-methyl glutaric acyl
coenzyme A reductase (HMG CoA reductase) in primary cultured rat hepatocytes and inhibit
the synthesis of cholesterol. In addition, Wan et al. (20) suggested that the hypocholesterolemic
functions of CGA are most likely due to the increase in fatty acid utilization in the liver via the
upregulation of peroxisome proliferation-activated receptor 𝛼 mRNA. Waterman et al. (23)
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also evaluated the effect of supplementation of 5% moringa concentrate (MC, delivering 66
mg/kg/d of moringa isothiocyanates) in obese-induced mice with very high-fat diet for 12
weeks. They found a reduction of gene expression of pro-inflammatory markers, TNFα, IL-6
and IL-1β in the liver and ileum tissues in mice treated with Moringa concentrate compared to
the control group.

Quercetin, another bioactive component in Moringa has been shown to improve hepatic lipid
accumulation in various pathways, such as the synthesis, transport and oxidation of long-chain
fatty acids and TG by suppressing the expression of two lipogenic genes SREBP-1c and FAS.
As a result, quercetin has the therapeutic potential for preventing or treating NAFLD and IRrelated metabolic disorders (24).

5.2 Materials and methods
5.2.1 Hepatic Lipids
Ten mg of liver for each sample was homogenized with 200 µL of chloroform/ isopropanol/
MP40 (7:11:01). The slurries were centrifuged and the supernatant was dried at 50°C overnight.
The quantification for total and free cholesterol was done with enzymatic assays kits (Wako
Diagnostics) according to Carr et al (25).The esterified cholesterol fraction was calculated
manually by subtracting free cholesterol from total cholesterol (26). Liver triglycerides were
analyzed by enzymatic methods (Wako Diagnostics, CA) (27).

5.2.2 Oxidized LDL

Tissue total protein was extracted using RIPA buffer and total protein concentrations of the
lysates were determined using the BCA Protein Assay Kit (Cell Signaling Technologies Inc,
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Beverly, MA). Hepatic oxLDL was measured with a specific guinea pig OxLDL ELISA kit
(MyBioSource), which measures a specific fraction of the apo B molecule (28).

5.2.3 Hepatic inflammatory cytokines
The potential of the Moringa leaves as an anti-inflammatory agent was evaluated by measuring
the cytokines in liver homogenates. To ensure that there was no interference with other liver
components in the assay, the protein was extracted and quantified as detailed before for the
oxLDL measurement. IL-1 beta, IL-6, IL-10, IFN-gamma, MCP-1, and TNF-alpha were
measured using Luminex technology with the MILLIPLEX MAP Rat Cytokine Immunoassay
kit (Millipore corporation, Charles, MO, USA) (27).

5.2.4 Liver histology
Small pieces taken from the same liver section were immersed in 10% buffered formalin.
Formalin-fixed livers were paraffin embedded and sections 3–5 μm were prepared and stained
with hematoxylin and eosin and scored by a pathologist blinded to the treatment.

5.2.5 Liver enzymes
Both AST and ALT were measured with direct enzymatic reactions and photometric detection
using the Cobas c111 analyzer (Roche Diagnostics).

5.2.6 Gene expression
Total RNA was extracted from the liver using the GenElute Mammalian Total RNA
Purification Kit, according to the vendor’s specifications (Sigma-Aldrich). Samples were lysed
and homogenized in guanidine thiocyanate and 2-mercaptoethanol to release RNA and
inactivate RNases. Resulting lysates were spun through a filtration column to remove cellular
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debris and shear DNA. The filtrate was then applied to a high capacity silica column to bind
total RNA, followed by washing and elution. To check the integrity of the extracted RNA,
samples were electrophoresed through a 1% agarose gel at 125V for 45 minutes. cDNA was
synthesized for each gene using cDNA synthesis kit following the manufacturer’s instructions.
cDNA was then amplified using Real Time PCR. The primers used for -actin, a house-keeping
gene, were taken from guinea pig sequences as previously reported (29).The genes selected to
be measured in this study were the following: DGAT2, CD68, PPARɤ, SREBP1 and LDL-R.

5.2.7 Statistical Analysis
Differences among groups in hepatic lipids, liver enzymes, inflammatory cytokines and gene
expression of regulators of lipid synthesis and uptake were analyzed by one-way ANOVA and
LSD post hoc analysis. Pearson correlations were calculated between plasma liver enzymes
and oxidized LDL P < 0.05 was considered to be significant. All analyses were conducted on
SPSS for Windows, Version 20 (IBM Corp.). All data are presented as mean ± SD.

5.3 Results
5.3.1 Hepatic Lipids
Hepatic total cholesterol, cholesteryl esters (CE) and triglycerides (TG) were significantly
lower (P<0.05) in the group fed the HM diet, while the concentrations of hepatic lipids in the
LM group were not different compared with HM or control groups. Free Cholesterol
concentration was significantly lower in both Moringa groups compared to control group
(Table 5.1).
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5.3.2 Oxidized LDL

As shown in Table (5.1), there were no significant differences in the concentration of OxLDL
between both Moringa groups and control.

5.3.3 Liver histology
There was a lower degree of steatosis and lipid accumulation in livers from the guinea pigs fed
the HM diet compared to the control and the LM group (Figure 5.2). Liver samples from
guinea pigs fed the control diet showed most lipid accumulation while the LM group exhibited
less accumulation than the control in agreement with hepatic cholesterol and triglyceride
concentrations.

5.3.4 Liver enzymes
Both moringa groups had lower concentration of ALT than the control group, while no
difference in the AST between groups were observed (P<0.05) (Table 5.2). A significant
correlation was found between liver enzymes and oxidized LDL (Figure 5.1)

5.3.5 Hepatic inflammatory cytokines
Hepatic cytokines; interleukin 1 beta (IL-1β), interleukin 10 (IL-10) and Interferon gamma
(IFNγ) were lowest significantly (P<0.05) in group fed the HM diet, intermediate in the low
moringa group and highest in control group. There were no differences in hepatic cytokines;
interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1) and tumor necrosis factor alpha
(TNFα) among different groups (Table 5.3).
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5.3.6 Gene expression
Guinea pigs group fed on high Moringa (HM) diet had lower levels of LDL receptor (LDL-R)
gene expression compared to control and LM groups. Guinea pig fed the moringa leaves had
lower gene expression of cluster of CD68 and SREBP1 compared to control (p<0.05). DGAT2
and PPARγ were lowest in the HM group; intermediate in LM and highest in the control group
(P < 0.05) (Figure 5.3).

5.4 Discussion
In the current study, we have demonstrated that Moringa leaves (ML) effectively reduce
hepatic steatosis in guinea pigs most likely by the action of polyphenols present in ML, mainly
CGA and quercetin, which have been shown to alter gene expression of major regulators of
hepatic cholesterol and TG synthesis and uptake. Also, we observed that, there was a dose
response with the HM diet having better effects overall on liver health.

5.4.1 Hepatic lipids
The cholesterol challenge used in the present study was found to cause hepatic steatosis in
guinea pigs as previously reported (11). Accumulation of lipids both cholesterol and TG were
observed in the control animals, while the intake of ML resulted in lower concentrations of
cholesterol and TG in a dose-dependent manner. CGA is one of the bioactive components
present in ML (30). Other investigators have reported that CGA markedly decreases the
concentration of total cholesterol and TG in liver (18) and in agreement with our results, these
hypolipidemic effects have also been observed in cells (31).

It is well known that hepatic steatosis is defined as accumulation of TG and fatty acids in the
hepatocytes and the presence of increased hepatic free cholesterol (FC) concentration could
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accelerate the development of NAFLD and NASH and also contribute to lipotoxicity and liver
injury (32,33). Thus the observed decreases in FC by Moringa intake confirm that Moringa can
be successfully used to prevent hepatic steatosis.

Moringa leaves have also been reported to decrease lipid accumulation in liver, heart and aorta
in hypercholesteremic rabbits and increase the excretion of fecal cholesterol (13). CGA has
also been demonstrated to inhibit 𝛽-hydroxy-𝛽-methyl glutaric acyl coenzyme A reductase
(HMG CoA reductase), the rate liming enzyme of cholesterol synthesis and improved lipid
metabolism by the transcriptional activation of AMPK and inhibition of downstream targets,
such as SREBP2 and HMGCR, to suppress the TC synthesis and TG levels in liver cells. CGA
also increased ABCA1 and CYP7A1 to enhance TC efflux and bile acid transport, synthesis,
and excretion (22, 34).

5.4.2 Oxidized LDL

OxLDL is a mixture of lipoproteins with heterogeneous modifications such as oxidation of
phospholipids, modification of apolipoprotein B (apoB) with malondialdehyde and aggregation
of apoB. These particles are defined as biomarker for atherosclerosis and in addition they can
exhibit pro-inflammatory, immunogenic, apoptotic, and cytotoxic activities for other diseases,
including NAFLD (35,36). OxLDL particles were showing to be trapped in the lysosome
compartment leading to presence of cholesterol crystals which can activate the inflammasome
and induce the activation of NF-κB signaling, therefore, OxLDL derived lysosomal lipid
accumulation can been linked to hepatic inflammation, liver fibrosis and the progression of
NASH (37,38).

In our study, no significant effect of Moringa leaves in altering the

concentration of OxLDL in the liver was observed when compared to control group. Thus the
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protective effects of Moringa in decreasing hepatic steatosis are not related to OxLDL
concentrations in the liver

5.4.3 Liver histology and liver enzymes
Histology evaluation indicated low hepatic lipid accumulation in the high moringa group,
intermediate in the low moringa group and high in the control group in total agreement with
hepatic lipids and inflammatory markers. When there is an injury to the liver, there is an
increase in serum concentrations of amino-transferases: AST and ALT. These enzymes are
highly concentrated in the liver although AST is also diffusely represented in the heart, skeletal
muscle, brain and kidneys suggesting that an elevation in plasma ALT is more specific for liver
injury (6).

Quercetin has been shown to inhibit the development of NASH by reducing macrovesicular
steatosis, microvesicular steatosis, hepatocellular ballooning and inflammatory infiltrate. This
effect was accompanied by a significant reduction in AST and ALT, lipid peroxidation,
inflammation and DNA damage (39). Moringa leaves in the present study were also found to
have a hepatoprotective effect, which could be partly due to the presence of quercetin, a wellknown flavonoid with hepatoprotective activity (8, 9, 40).

It is well known that, high levels of AST and ALT in serum are indicators for liver dysfunction.
High concentration of Moringa oleifera leaves were shown to improve liver functions (41).
Confirmed by Buraimoh (42) and Halaby et al (43), Moringa leaves have shown significant
hepato-protective activity and can protect the liver from chemically induced damage. Other
studies showed a reduction of serum ALT and AST in animals treated with the extract of
Moringa oleifera leaves (7, 44, 45).
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5.4.4 Hepatic inflammatory cytokines
The many bioactive compounds naturally present in Moringa oleifera leaves, such as
flavonoids and phenolic acids, might be involved in the anti-inflammatory process. Among
them, quercetin inhibited activation of NF-kB and also the subsequent NF-kB-dependent
downstream events and inflammation (46).

In the present study, the HM moringa group, the inflammatory cytokines, IL-1β and IFNγ were
27 and 21% lower, respectively compared to the control (p< 0.05), while the concentrations for
these cytokines were intermediate for the low Moringa group. IL-1β is an important marker
for hepatic damage because in liver disease, IL-1β promotes the recruitment of inflammatory
cells to the liver, which contributes to fibrosis, an important characteristic of the progression
from hepatic steatosis to steatohepatitis (47).

The anti-inflammatory effects of extract of MO leaves in rats fed with an atherogenic diet in
order to induce hyperlipidemia were investigated by Rajanandh et al. (48). They showed serum
TNF-α and IL-1 was significantly lower in rats treated with extract of MO leaves compared to
control. Also, a reduction of gene expression of pro-inflammatory markers, TNFα, IL-6 and
IL-1β was found in the liver and ileum tissues in mice with very high-fat diet which treated
with Moringa oleifera concentrate (23). Moreover, both MO leaves extract and quercitin downregulated the expressions of iNOS, interferon gamma (IFN-γ) and C reactive protein (CRP)
compared to the group only fed with high-fat diet. Finally, release of serum inflammatory
cytokines TNF-α and IL-6 potently decreased in the group treated with the extract of MO leaves
compared to a high fat fed group (46). Mahajan et al. (49) reported that MO leaves were
effective in blocking production of several cytokines including TNF-α, IL-4, and IL-6 and
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might be due to additional mechanisms such as mast cells stabilization and antispasmodic
activities, which could be another protective effect of Moringa (50).

5.4.5 Gene expression
It has been reported that hyperinsulinemia alters hepatic cholesterol homeostasis by increasing
nuclear SREBP-2 and LDL-R (30). SREBP-2 is a transcription factor that regulates cholesterol
biosynthesis (3) and the LDL-R in the liver is crucial for cholesterol regulation (51). DGAT1
is the enzyme that catalyzes the final step in triglyceride synthesis, and it has been reported to
be decreased after carotenoids treatment and high fat diets (3, 52).

However, decreased expression of hepatic HMG-CoA reductase is the primary response
employed by the animals to achieved cholesterol homeostasis in the face of a dietary
cholesterol challenge. This decrease in hepatic HMG-CoA reductase expression was
accomplished by a decrease in translational efficiency of the HMG-CoA reductase mRNA (53).
In the current study, no differences in HMGCR mRNA expression were observed between
experimental groups. However, the regulation of this enzyme is post-translational, not only
transcriptional. Thus, it is possible that Moringa might have affected the regulation of HMGCoA reductase post-translationally.

The LDL receptor (LDL-R) is an important regulator used by the liver to control cholesterol
levels in the body (54). Some studies have found that animals challenged with high-cholesterol
diets increased the expression of hepatic LDL-R and they have suggested that this response
might be utilized by the liver to help maintain cholesterol homeostasis (55). Increased
expression of the hepatic LDL receptor can help maintain cholesterol homeostasis by removing
LDL cholesterol from the blood. The increased dietary cholesterol reaches the liver by way of
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chylomicron remnants. The excess hepatic cholesterol can be incorporated into VLDL and
processed to intermediate density lipoprotein (IDL) and LDL by the action of lipoprotein lipase
(56). In this study, however, high concentration of Moringa oleifera leaves decreased the level
of LDL-R gene expression. This decrease in the LDL-R might be associated with the decreases
in hepatic cholesterol and the lack of effect of Moringa on plasma LDL cholesterol.

Interestingly, guinea pig consumed the HM had lower expression of LDL-R compared to the
other groups. The hepatic LDL-R is the major mechanism by which the body removes LDL
cholesterol from plasma and it has been shown that LDL-receptors (57) and LDL uptake are
up-regulated by soluble fiber (58,59). In this study, there were no differences in plasma
cholesterol among groups, while there was a very significant lowering of hepatic cholesterol
in the HM group suggesting that the decreased expression of LDL-R might have contributed
to the lack of effect in lowering plasma LDL-C and to the very significant lowering of hepatic
cholesterol.

SREBPs regulate the expression of target genes involved in cholesterol, fatty acid and
triglyceride syntheses. SREBP-1c and -2 predominates in the liver. SREBP-1 is associated with
fatty acid synthesis genes, while SREBP-2 has a preference for cholesterol synthesis genes;
however, all 3 isoforms can drive the expression of HMG-CoA-R by binding to its SRE in the
proximal promoter region of this gene (60,61).We observed decreases in SREBP-1c expression
in guinea pigs fed Moringa oleifera leaves compared to control. Gene expression of CD68 and
SREBP-1c were 60% lower in both the LM and HM groups compared to the control (p< 0.01).
CGA as has been shown in other studies could have also had an effect in decreasing TG via
reductions in SREBP1c (24).
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DGAT is the enzyme that catalyzes the final step in TG synthesis by adding a free fatty acid to
sn-1, 2- diacylglycerol (62). The enzyme has two isoforms, DGAT1 and DGAT2, however,
DGAT2 is the one primarily expressed in the liver (63). Studies with animal models have
suggested that this enzyme plays an important role in the development of hepatic steatosis (32).
In this study, the Moringa oleifera leaves groups showed a significant reduction of hepatic gene
expression of DGAT2 when compared to controls and this can explain the differences observed
in steatosis in the liver. The decreases in hepatic TG can also be associated with the lower
expression of DGAT2. The flavonoid quercetin has been shown to reduce TG synthesis in
Caco-2 cells in part, via reduction of DGAT activity (64). Since Moringa oleifera leaves have
significant concentrations of quercetin, we can speculate that this flavonoid might have been
involved in the decreased expression of DGAT-2 further contributing to the observed lower
concentrations of TG in the guinea pigs fed the ML (30).

PPARγ is expressed at high levels in adipose tissue, macrophages, endothelial cells and large
intestine but is also found in liver (65). PPARγ plays a major role in lipid and glucose
metabolism, in macrophage foam cell formation and inflammatory response and in
adipogenesis (66). Activation of PPARγ in adipocytes increased FA storage and TG synthesis
through increased expression of its target genes and increased secretion of adipokines resulting
in decreased lipid accumulation in other tissues. PPARγ expression level in hepatocytes was
linked with liver steatosis in rodents (67). Normal mice fed a HFD had an increased expression
of PPARγ2 in the liver (68). In our study, we showed that PPARγ were decreased in Moringa
oleifera leaves groups compared to control group (P < 0.05) (Figure 5.3).

5.5 Conclusions
In conclusion, a challenge with dietary cholesterol has a profound effect on hepatic cholesterol
homeostasis, which results in elevated hepatic total cholesterol, free cholesterol and
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triglyceride concentrations. However, the polyphenols present in Moringa oleifera leaves,
possibly chlorogenic acid and quercetin, regulated these genes involved in lipid synthesis and
uptake, resulting in lower concentrations of hepatic lipids. The lower lipids in liver due to
Moringa oleifera leaves intake were associated with lower inflammation caused by cholesterol
challenge and decreased hepatic steatosis.
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TABLES
Table 5.1 Concentration of hepatic total cholesterol, free cholesterol, cholesteryl ester and
Oxidized LDL of guinea pigs fed a hypercholesterolemic diet with no Moringa (control),

Low (10%), or High Moringa (15%)1

1

Control

Low Moringa

High Moringa

Total Cholesterol (mg/g)

10.9±2.8a

9.0±1.6ab

6.2±3.0b

Free Cholesterol (mg/g)

4.5±0.9a

3.2±1.0b

2.5±1.6b

Cholesteryl Esters (mg/g)

6.3±2.1a

5.8±1.1ab

3.8±1.8b

Triglycerides (mg/g)

50.9±11.9a

43.0±8.8ab

30.4±11.5b

Oxidized LDL (ng/g)

2.7±1.4

1.9±0.9

2.3±0.5

Values are means ± SD, n=8; Values in the same row with different superscripts are

significantly different at P<0.05
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Table 5.2 Plasma ALT and AST of guinea pigs fed a hypercholesterolemic diet with no
Moringa (control), Low (10%), or High Moringa (15%)1
Parameter

Control

Low Moringa

High Moringa

ALT (IU/L)

239.3±144.6a

109.4±43.7b

141.9±73.6b

AST(IU/L)

552.9±479.4

276.9±146.5

299.4±195.1

1

Values are means ± SD, n=8. Values in the same row with different superscripts are

significantly different at P<0.05
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Table 5.3 Hepatic cytokines of guinea pigs fed a hypercholesterolemic diet with no
Moringa (control), Low (10%), or High Moringa (15%)1

1

Parameter

Control

Low Moringa

High Moringa

IL-1β (ng/g)

196.4±49.2a

180.3±40.9ab

143.1±31.5b

IL-6 (ng/g)

30.1±3.7

27.5±4.9

37.3±16.4

IL-10 (ng/g)

233±54a

208±42ab

160±38b

IFNγ (ng/g)

194.4±20.5a

173.4±39.2ab

153.4±42.3b

MCP-1(ng/g)

11.4±1.1

10.3±1.2

21.9±21.9

TNFα (ng/g)

31.1±4.9

27.4±4.4

35.6±19.3

Values are means±SD, n=8; Values in the same row with different superscripts are

significantly different at P<0.05 using LSD as post-hoc test. IFNγ = Interferon gamma; MCP1= monocyte chemoattractive protein-1.
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FIGURES

Figure 5.1 Correlation between liver enzymes Alanine Aminotransferase (ALT) (r= 0.47,
P < 0.05) and Aspartate Aminotransferase (AST) ( r= 0.48, P < 0.05) and oxidized LDL
of guinea pigs fed a hypercholesterolemic diet with no Moringa (control), Low (10%), or
High Moringa (15%)
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Figure 5.2 Histological evaluation of guinea pigs fed a hypercholesterolemic diet with no
Moringa (control), Low (10%), or High Moringa (15%) (200x magnification)

Control

10% Moringa
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15% Moringa

Figure 5.3 Hepatic relative Gene expressions of male guinea pigs fed a
hypercholesterolemic diet with no Moringa (control), Low (10%), or High Moringa
(15%). Values are mean ± SD, n=8. Bars without a common letter differ at P < 0.05.
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Chapter 6
The Effects of Moringa leaves on Adipose tissue
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6.1 Background
Adipose tissue has a major role in the development of several metabolic-related diseases, such
as atherosclerosis, coronary heart disease (CHD) and type 2 diabetes (1). Adipose tissue is the
main site for triglyceride and cholesterol storage in humans as well as in other animal species
(2). Excessive accumulation of cholesterol can be toxic to several tissues, including heart, aorta,
and liver (3, 4, 5).

Several studies showed that increased cholesterol accumulation in epididymal adipose tissue
impaired adipocyte differentiation and maturation, induced insulin resistance and secretion of
pro-inflammatory cytokines, and stimulated macrophage (Mø) recruitment in LDL receptor
knock-out mice (LDLR -/-) (4). In addition, in adipose-derived stromal cells, cholesterol
accumulation leads to impairment of adipocyte development and function (6). Release of
cytokines, such as tumor necrosis factor (TNF)-α, resulted in infiltration of Mø, neutrophils,
T-cells, and other immune cells (7).

Obesity leads to hypertrophied adipocytes due to high TG and cholesterol accumulation,
resulting in abnormal cellular cholesterol distribution (8, 9). Overall, these features triggered
by lipid accumulation are hallmarks of dysfunctional adipocytes (10).

In liver, a major organ involved in cholesterol metabolism, hypercholesterolemia caused
hepatocyte dysfunction, fibrosis, and induction of the development of early stages of
nonalcoholic steatohepatitis. So, it is important to evaluate the effects of hypercholesterolemia
on other major organs of cholesterol metabolism and storage, such as adipose tissue (11).
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It has been reported that obesity leads to hypertrophy of adipocytes due to high TG and
cholesterol accumulation resulting in abnormal cellular cholesterol distribution with decreased
plasma membrane (PM) cholesterol and increased fluidity in these cells (12, 13). Overall, these
characteristics triggered by TG and cholesterol accumulation are hallmarks of dysfunctional
adipocytes (14).

In guinea pigs, we have demonstrated that high hepatic cholesterol concentrations induce the
development of the initial stages of nonalcoholic steatohepatitis and fibrosis (11). Our previous
study indicated that Moringa leaves (ML) prevented hepatic steatosis and reduced the level of
pro-inflammatory cytokines compared to a control diet where no moringa was provided. ML
has also been shown to reduced lipid accumulation in adipocytes in other animal species (15).

Guinea pigs have several similarities to humans in lipoprotein and cholesterol metabolism and
are considered a good model for study of diet-induced atherosclerosis (16, 17). For this study,
we are using guinea pigs as animal models to study adipose tissue inflammation induced by a
high cholesterol diet as well as the potential beneficial effects of Moringa leaves in protecting
against the recruitment of macrophages and the release of inflammatory cytokines.

In a study conducted in rats, fat accumulation in the thoracic and abdominal regions due to a
high fat, high cholesterol diet was reported. The observed increases in body weight were
postulated to be due to excessive energy intake, which led to adipose tissue accumulation (18).
In addition, positive correlations between daily lipid intake and body mass index as well as fat
deposition have been reported (19). The reduction in these measures in obese rats resulted from
treatment with Moringa oleifera, which may be associated with less utilization of dietary lipids.
Dongmeza and co-workers found (15) that a high level of moringa extract or its fractions such
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as saponins and tannins resulted in reduced energy leading to decreased protein and lipid
biosynthesis. Therefore, moringa has the ability to reduce body lipid and consequently energy
retention.

The objective of the present study was to evaluate the effects of a high cholesterol dietary
challenge on cholesterol tissue accumulation and inflammation in guinea pigs and whether ML
would protect against these metabolic alterations.

We hypothesized that high dietary cholesterol would induce cholesterol accumulation, and
inflammation in adipose tissue and that ML would protect against these metabolic
abnormalities

6.2 Materials and Methods
6.2.1 Cholesterol in adipose tissue
Epididymal adipose tissue (0.12 g) was homogenized and 15 ml of chloroform-methanol 2:1
(v/v) were added and tubes were incubated at 60°C overnight. After adding 1.6 mL of 0.05%
sulfuric acid (H2SO4) to each tube, samples were centrifuged at 3,000 rpm for 10 min. at room
temperature and dried under nitrogen. Total cholesterol was measured using enzymatic kits
(WakoChemicals USA, Inc., Richmond, VA) according to Carr et al (20).

6.2.2 Inflammatory Cytokine Concentration in the adipose tissue
Tissue total protein was extracted using RIPA buffer and total protein concentration of the
lysates was determined using the BCA Protein Assay Kit (Cell Signaling Technologies Inc,
Beverly, MA) (21). Using the same concentration of protein for all samples, the following
cytokines were measured using Luminex technology (Luminex MAGPIX System, Austin, TX)
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with the MILLIPLEX MAP Rat Cytokine Immunoassay kit (Millipore corporation, Charles,
MO, USA): IL-1β, IL-6, IL-10, IFN-γ and monocyte chemotactic protein 1 (MCP-1), as
previously described (19).

6.2.3 Histological evaluation
Small pieces of adipose tissue samples were immersed in 10% buffered formalin. Formalinfixed adipose tissues were paraffin embedded and 3–5 μm sections were stained with
hematoxylin and eosin. Histological evaluation was performed in two separate occasions by a
veterinary pathologist blinded to the treatments. A low magnification screen of the entire tissue
was assessed for evidence of abnormality, and crown-like structures and signs of inflammation
were quantified in 10 fields at 200X.

6.2.4 Statistical Analysis:
Differences between groups were analyzed by one-way ANOVA and Fisher’s LSD post hoc
analysis. p<0.05 was considered to be significant. All analyses were conducted on SPSS for
Windows, Version 20 (IBM Corp.)

6.3 Results
6.3.1 Cholesterol accumulation and inflammation scores
There was no significant difference in the total cholesterol in the adipose tissue nor any
difference in the inflammation scores among of guinea pigs fed high moringa, low moringa
and control group as shown in Table 6.1.
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6.3.2 Inflammatory cytokine concentrations in the adipose tissue
There were no significant differences in the inflammatory cytokine concentrations; IL-1β, IL6, IL-10, IFN-γ, TNFα and MCP-1 among groups of guinea pigs fed high moringa, low moringa
and control group as shown in Table 6.1.

6.3.3 Histological evaluation
Adipocytes from all guinea pigs contained abundant lipid irrespective of diet. The majority of
the guinea pigs did not have signs of inflammation (Figure 1, Panel A); 2 of the guinea pigs
fed the ML had inflammation (Figure 1, Panel B). Histological CLS scores are also presented
in Table 6.1. A representative figure of tissue histology for most guinea pigs (Panel A) and for
one of the guinea pigs showing crown-like structures (Panel B) is presented in Figure 6.1.

6.4 Discussion
6.4.1 Cholesterol accumulation in the adipose tissue
Guinea pigs are a good model for study of chronic inflammatory diseases. Previous studies
showed that cholesterol challenge can induce atherosclerosis, and hepatic cholesterol
accumulation (16, 22, 23). Studies showed that cholesterol synthesis in adipose tissue only
accounts for 4% of that produced in the liver, therefore, most of the cholesterol in the adipocyte
is delivered by lipoprotein-mediated mechanisms (24).

Cholesterol can be delivered into the adipocyte through HDL scavenger receptor B1 (SREBP1)
–independent (25, 26) or –dependent mechanisms (27) and LDL receptor and oxidized-LDL
(ox-LDL) scavenger receptor pathways (28, 29). HDL-cholesterol removal by SREBP1 takes
place in the caveolae (a specific plasma membrane lipid raft) where SREBP1 binds HDL and
extracts cholesterol ester (CE). In caveolae, CE can be taken up by HDL or internalized into
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an intracellular membrane compartment (30). In the SREBP1–independent mechanism via CE
transfer protein (CETP), CE is transferred from HDL to a specific plasma membrane
compartment, and then apoE is secreted into this compartment and acquires CE. Finally, apoE
loaded with CE is directed to the extracellular matrix and recaptured by the LDL receptor–
related 1 protein (26). Another cholesterol source for the adipocyte is ox-LDL. This lipoprotein
enters the adipocyte through the SREBP1, or ox-LDL receptor 1 and is further proteolytically
degraded (28).

Unexpectedly, no effect of Moringa leaves on cholesterol accumulation in the adipose tissue
was observed in this study. These results might be related to the lack of effect of Moringa in
reducing plasma LDL cholesterol or oxidized LDL (chapter 4) that we observed or that the 6week study period was too short to manifest any beneficial effect.

6.4.2 Inflammatory cytokine concentrations in the adipose tissue
In this study, there were no differences in inflammatory cytokine concentrations in the adipose
tissue among groups. In the previous studies, cholesterol challenge diets were shown to
increase levels of Ox-LDL (22). This pro-atherogenic lipoprotein is internalized by SR-B1 and
LRP-1 in Mø and smooth muscle cells leading to cell dysfunction and release of proinflammatory cytokines and chemo-attractants and formation of foam cells which are the
hallmark of atherosclerosis (31).

The amount of cholesterol in the adipose was greater than what has been observed in guinea
pigs fed a low cholesterol diet (32). Cholesterol deposition in adipose tissue increased
macrophage infiltration associated with high levels of inflammatory cytokines TNF-α, MCP1, and GMF-CSF. Also, cholesterol accumulation led to decreased gene and protein expression
of SREBP-1 and PPAR-γ2 resulting in adipocyte dysfunction and blunted cell development
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(6). Expression of SREBP-1 showed to directly modulate the expression of the PPARγ gene at
the transcription level (33), which directly involved in the transcription of several lipogenic
genes that are important in adipocyte development (34).

Dysfunctional adipocytes are found to be more receptive to TNF-α signaling and subsequent
apoptosis, which associated with macrophage infiltration and secretion of inflammatory
cytokines (4).

None of these metabolic alterations were observed in the 6-week intervention in this study
indicating that a longer time of feeding is needed to have the presence of dysfunctional
adipocytes associated with the high cholesterol feeding. The increases in cholesterol
accumulation and the release of inflammatory cytokines were present in all guinea pigs since
the inclusion of ML in the diet did not affect the higher cholesterol uptake associated with the
dietary intervention (32).

6.5 Conclusion
Moringa leaves had no effect in protecting the adipose tissue against inflammation in guinea
pigs fed a high cholesterol diet. It is clear that Moringa exerted its main effects in the liver
(Chapter 5) where substantial reductions in lipid accumulation and in inflammation were
observed. The lack of effect of Moringa in reducing plasma cholesterol explains why
cholesterol accumulation in the adipose was not reduced leading to inflammation and
macrophage accumulation. Further studies need to be conducted with longer feeding times for
Moringa to assess if plasma lipids could be reduced and therefore cholesterol accumulation in
the adipose could also be lowered.
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TABLES
Table 6.1 Concentration of cholesterol, histological scores and inflammatory cytokines in
adipose tissue of guinea pigs fed a hypercholesterolemic diet with no Moringa (control),
Low (10%), or High Moringa (15%) 1
Parameter
Total Cholesterol

Control

Low Moringa

High Moringa

12.77± 3.82

10.91±1.23

0.12 5± 0.18

0.17 5± 0.31

11.60±1.50

(mg/g)
Histological scores
IL-1β (ng/g)

30.0 ± 12.4

25.2 ± 7.3

36.2 ± 19.3

IL-6 (ng/g)

16.8 ± 2.3

15.2 ± 2.9

17.3 ± 3.1

IL-10 (ng/g)

40.7 ± 15.3

32.2 ± 12.1

47.5 ± 19.8

IFN-γ (ng/g)
MCP-1(ng/g)

TNFα (ng/g)
1

0.150 ± 0.18

116.3 ± 25.2

95.3 ± 31.8

7.0 ± 1.00

14.2 ± 1.2

7.0 ± 1.1

7.2 ± 0.8

13.7 ± 2.4

15.0 ± 3.4

Values are presented as mean ± SD for n= 8 guinea pigs per group
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107.0 ± 24.9

Figures
Fig 6.1 Representative histological evaluation of adipose tissue as observed in the
majority of the guinea pigs (Panel A) and histological evaluation of one of two guinea pigs
showing evidence of inflammation and macrophage infiltration (Panel B).

Panel A
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Panel B
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Conclusions and future directions
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7.1 Conclusions
This project demonstrated that MO leaves do protect against hepatic steatosis by reducing
hepatic lipid accumulation and inflammation although no positive effects were observed on
plasma lipids or adipose tissue inflammation.

However, MO leaves appeared to affect HDL metabolism by decreasing the medium HDL,
which has been considered a less protective HDL and by increasing LCAT activity. These
results suggested a potential role of MO leaves in modulating RCT.

Higher concentration of Moringa leaves were found to be more effective in protecting hepatic
tissue against cholesterol-induced damage as the high Moringa groups showed lower
concentrations of both total and esterified cholesterol, plasma alanine aminotransferase (ALT),
hepatic cytokines; interleukin 1 beta (IL-1β), interleukin 10 (IL-10) and Interferon gamma
(IFNγ), DGAT2 and PPARγ mRNA expression. An unexpected finding was that there were no
differences in plasma or hepatic oxidized LDL (OxLDL) suggesting that Moringa leaves are
not such potent antioxidants.

A challenge with dietary cholesterol has a profound effect on hepatic cholesterol homeostasis,
which results in elevated hepatic total cholesterol, free cholesterol and triglyceride
concentrations. However, the polyphenols present in Moringa oleifera leaves, possibly
chlorogenic acid and quercetin, regulated the genes involved in lipid synthesis and uptake,
resulting in lower concentrations of hepatic lipids and protection against liver inflammation.

Moringa leaves had no effect in protecting the adipose tissue against inflammation in guinea
pigs fed a high cholesterol diet. The lack of effect of Moringa leaves in reducing plasma
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cholesterol explains in part why cholesterol accumulation in the adipose was not reduced
leading to inflammation and macrophage accumulation.

7.2 Future directions
The importance of conducting these studies is to cover the gaps in current knowledge regarding
the use of Moringa leaves as medication in the prevention or treatment of NAFLD, T2DM, and
CVD. With the completion of the three aims, there is a better understanding on how Moringa
leaves containing bioactive compounds affected plasma lipids, hepatic steatosis and
inflammation in liver and about the lack of effects in plasma and the adipose tissue. However,
there are still questions that remaine unanswered after the completion of the study.

An important limitation in this project was the lack of a positive control group. A similar study
should be conducted using a control with guinea pigs receiving the same diet without
cholesterol and without Moringa leaves. This will help us clarify how much Moringa leaves
protect against hepatic steatosis by comparing the measured parameters with animals where
hepatic steatosis is not induced.

Also, we have little information about the effects of Moringa leaves in guinea pigs in longer
periods of time to determine if a more extended period of feeding would have an effect in
decreasing plasma cholesterol as was observed in other animal studies and therefore reducing
cholesterol accumulation in the adipose tissue and inflammation Also, it is important to
determine accurate concentrations of bioactive components in Moringa and which of these
compounds present in Moringa leaves can ameliorate the deleterious effects of a cholesterol
challenge.
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The high contribution in bioactive compounds may explain the pharmacological properties
ascribed to Moringa oleifera leaves. Many in vitro and in vivo studies in animals have
confirmed these properties. However, few studies on human beings are available. Therefore, it
is too early to recommend Moringa oleifera leaves as medication in the prevention or treatment
of cardiovascular disease and dyslipidemia. Further studies aimed to confirm the
pharmacological effects of moringa in humans and, at the same time, ensuring its safety during
chronic or long-term use should be encouraged.

For future perspectives, a similar study should be conducted regarding the use of Moringa
leaves as a medication in the treatment of obesity and CVD and to determine whether it is safe
to move forward to perform clinical trials. In vitro studies should be done before clinical trials
can be conducted.

It is unclear whether the hypocholesterolemic effect of Moringa leaves was associated with
repressed de novo cholesterol biosynthesis, increased hepatic cholesterol clearance or increased
intestinal excretion. It might be interesting to find the physiological basis of decreases in
hepatic steatosis following Moringa treatment.

Besides a rationalized investigation of the therapeutic effect of M. oleifera leaves, it is possible
to conduct an unbiased search for the affected physiological pathways. This could be achieved
by globally comparing tissues or fluids of untreated and treated animals or humans.

Further exploration of the eventual use of Moringa oleifera therapy in humans will require that
reference standards be set for its cultivation, the collection of its parts, as well as for their final
conditioning under good agricultural and collection practices. Furthermore, when the
pharmacological basis of the therapeutic effects on a particular pathology is rationally well
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circumscribed, standardized assays should be required to evaluate relevant properties. For
example, on the basis of current knowledge, it would be indicated that the content of fiber,
phytosterols as well in antioxidant and anti-inflammatory activities be evaluated and
documented in Mopringa oleifera formulations destined to the treatment of atherosclerosis or
diabetes.
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